FDA Calendar

Biotech Stock Catalyst and FDA Calendar for your biotech stock investing. Use our tools on your road to profit in the stock market. Biotech stocks with key binary events/catalysts - FDA Approval/PDUFA, Advisory Committee and Phase 2 & 3 trial data releases dates.

Refer to the Biotech Historical Catalyst Calendar for completed biotech stock catalysts.

The catalyst date is the LATEST expected date for the catalyst to occur by.  For example, if the catalyst date is 12/31/17, the event is expected to occur BY 12/31/17. It does NOT necessarily mean that the catalyst will occur ON this date. In most cases it will occur BEFORE.

Please refer to the "FDA Calendar Glossary" for a list of terms used in the FDA Decision Calendar.

LARGE CAP CATALYSTS - generally only Phase 3 catalysts noted in company presentations and/or earnings releases are shown.

PDUFA DATES - biosimilars and sNDA/sBLA filings and resubmissions are only noted if a PDUFA date has been released by the company. No official PDUFA date = No entry (e.g. Saxagliptin and dapagliflozin resubmission). Standard reviews for NDA/BLA filings use a 10 month estimate following filing acceptance for a NEW MOLECULAR ENTITY if no PDUFA date has been announced.

Pipeline data are current and updated daily! Click on the date for the source of the catalyst.


Financial data are delayed 15-35 minutes.

Subscribe HERE to ensure you receive your weekly FREE copy of the BioPharmCatalyst Biotech Stock Watch list and/or our daily option of Biotech Stock Price Movers and Pipeline Database updates


Showing 472 drugs
Ticker Price Drug Stage Catalyst
ACRS
$24.85
+0.13  (+0.52%)
A-101
Seborrheic keratosis (SK)
PDUFA
PDUFA date is December 24, 2017.
AGRX
$4.53
-0.01  (-0.23%)
Twirla
Contraceptive patch
PDUFA
CRL issued 2013. Phase 3 top-line data released January 3, 2017 - poor data. NDA resubmitted with PDUFA date of December 26, 2017
VRX
$20.03
+0.34  (+1.75%)
Luminesse
Eye Brightener
PDUFA
PDUFA date December 27, 2017.
AEZS
$2.22
-0  (-0.19%)
Macimorelin Acetate - Macrilen
Adult Growth Deficiency
PDUFA
CRL issued November 2014. Phase 3 data released January 4, 2017 - trial failed. NDA resubmitted with new PDUFA date of December 30, 2017.
ABBV
$97.47
+1.17  (+1.21%)
Risankizumab
Psoriatic Arthritis
Phase 2b YE 2017
Phase 2b data due 2017.
BIIB
$326.39
+2.84  (+0.87%)
BAN2401 (Aβ mAb)
Alzheimer’s disease
Phase 2 YE 2017
Phase 2 data due around the end of 2017.
BPTH
$0.23
+0  (+1.09%)
Prexigebersen
Acute myeloid leukemia (AML)
Phase 2 YE 2017
Phase 2 first patient enrolled November 2016. Interim analysis due by the end of 2017.
CALA
$8.35
-0.1  (-1.19%)
CB-839 with paclitaxel
Triple negative breast cancer
Phase 2 4Q 2017
Phase 2 data due 4Q 2017.
CELG
$109.32
+1.08  (+0.99%)
REVLIMID - RELEVANCE
Newly Diagnosed Follicular Lymphoma
Phase 3 2H 2017
Phase 3 data due 2H 2017.
CELG
$109.32
+1.08  (+0.99%)
OTEZLA
Ulcerative Colitis
Phase 2 YE 2017
Phase 2 data due by the end of 2017.
CELG
$109.32
+1.08  (+0.99%)
GED-0301
Ulcerative Colitis
Phase 2 2H 2017
Phase 2 data due 2H 2017.
DCTH
$0.06
+0  (+1.69%)
Melphalan Hepatic Delivery System (Melphalan HDS)
Hepatocellular carcinoma (HCC) - cancer
Phase 3 4Q 2017
CRL issued September 13, 2013. New Phase 3 initiated February 2016. Ongoing as of November 2016. Interim safety analysis due by the end of 2017.
EDGE
$9.24
+0.17  (+1.87%)
EG-1962
Improving patient outcomes following an aneurysmal subarachnoid hemorrhage (aSAH)
Phase 3 Late-2017
Phase 3 ongoing. Futility analysis late 2017. Interim top-line data due 1Q 2018. Full top-line data due late 2018.
GILD
$75.29
+0.94  (+1.27%)
GS-9674
Primary biliary cholangitis
Phase 2 4Q 2017
Phase 2 interim analysis due 4Q 2017.
KALA
$16.33
+0.02  (+0.12%)
INVELTYS
Dry eye disease
Phase 3 YE 2017
Phase 3 data due by the end of 2017.
KALA
$16.33
+0.02  (+0.12%)
INVELTYS
Dry eye disease
Phase 3 YE 2017
Phase 3 data due by the end of 2017.
MLNT
$15.85
+0.65  (+4.27%)
Taksta - Fusidic acid
Refractory infections in bones and joints
Phase 2/3 YE 2017
Phase 2/3 data due by the end of 2017.
MRK
$56.33
+0.32  (+0.57%)
Ertugliflozin
Type 2 diabetes
PDUFA December 2017
PDUFA date set for December 2017 - exact date not provided. December 31 entered as latest possible date for calendar entry purposes only.
MRSN
$17.47
-0.51  (-2.84%)
XMT1522
HER2 - breast cancer
Phase 1 YE 2017
Phase 1 safety data due around the end of 2017.
NLNK
$8.28
+0.03  (+0.36%)
Indoximod + gemcitabine and nab-paclitaxel
Pancreatic cancer
Phase 2 2H 2017
Phase 2 data due 2H 2017.
NVAX
$1.32
-0.01  (-0.76%)
NanoFlu vaccine
Influenza
Phase 1/2 4Q 2017
Phase 1/2 initiation announced September 19, 2017 with data due 4Q 2017.
OCRX
$1.79
+0  (+0%)
OCR-002
Cirrhosis
Phase 2a YE 2017
Phase 2a trial initiation announced June 1, 2017. Top-line data due by the end of 2017.
OGEN
$0.29
+0  (+0.2%)
AG013
Oral mucositis (OM)
Phase 2 YE 2017
Phase 2 dosing announced August 30, 2017. Preliminary data due by the end of 2017 with completion and full results due by the end of 2018.
PFE
$37.07
+0.6  (+1.65%)
Ertugliflozin
Type 2 diabetes
Phase 3 December 2017
PDUFA date set for December 2017 - exact date not provided. December 31 entered as latest possible date for calendar entry purposes only.
PFE
$37.07
+0.6  (+1.65%)
BOSULIF
First-Line Treatment of Philadelphia Chromosome Positive Chronic Myeloid Leukemia
PDUFA priority review December 2017
Phase 3 trial met primary endpoint - December 2016. PDUFA date under priority review for sNDA filing December 2017. Exact date not provided.
PHMMF
$2.78
+0  (+0%)
Zepsyre(PM1183)
Ovarian cancer
Phase 3 YE 2017
Phase 3 data due end of 2017
RDUS
$29.06
+0.4  (+1.39%)
Elacestrant
Vasomotor symptoms
Phase 2b YE 2017
Development update due by end of 2017.
RGNX
$28.58
+0.42  (+1.5%)
RGX-501
Homozygous familial hypercholesterolemia (HoFH)
Phase 1/2 YE 2017
Phase 1/2 dosing initiated - March 8, 2017. Interim data due by the end of 2017.
RNN
$1.93
-0.01  (-0.52%)
Supinoxin
Triple negative breast cancer
Phase 2a 4Q 2017
Phase 2a initial data due 4Q 2017.
RNN
$1.93
-0.01  (-0.52%)
RX-3117
Relapsed and refractory pancreatic cancer
Phase 2 4Q 2017
Updated Phase 2a data presented at ASCO GI January 20, 2017. Further data due 4Q 2017.
RNN
$1.93
-0.01  (-0.52%)
Archexin
Renal cell carcinoma (RCC) - cancer
Phase 2a 4Q 2017
Phase 2a second stage enrollment commenced February 2016. Initial data due 4Q 2017.
RVNC
$32.50
+0.35  (+1.08%)
RT002
Plantar fasciitis
Phase 2 YE 2017
Phase 2 completion of enrollment noted October 18, 2017. Data due towards the end of 2017.
RXII
$0.65
+0.02  (+3.14%)
RXI-109-1402
Connective tissue growth factor (CTGF)
Phase 2 YE 2017
Phase 2 final readout due by the end of 2017.
RXII
$0.65
+0.02  (+3.14%)
Samcyprone - RXI-SCP-1502
Cutaneous warts
Phase 2 YE 2017
Phase 2 enrollment completed - noted September 6, 2017. Data read outs due before the end of 2017.
SAGE
$159.90
+1.86  (+1.18%)
SAGE-217
Essential tremor
Phase 2 4Q 2017
Announced that screening has opened for Phase 2a trial - December 13, 2016. Data due 4Q 2017.
TCON
$3.00
+0.05  (+1.69%)
TRC105
Soft tissue sarcomas
Phase 2 2H 2017
Phase 2 data due 2H 2017.
VNDA
$14.15
+0.1  (+0.71%)
HETLIOZ (tasimelteon)
Jet Lag Disorder
Phase 2 4Q 2017
Phase 2 data due in 4Q 2017.
EIGR
$12.00
-0.1  (-0.83%)
Ubenimex - LIBERTY
Pulmonary arterial hypertension (PAH)
Phase 2
Phase 2 initiated July 2016. Enrollment completion announced May 15, 2017 with data due 1Q 2018 at JPM Conference - January 8-11, 2018.
BOLD
$28.65
-0.21  (-0.73%)
AT132 - ASPIRO
X-Linked Myotubular Myopathy
Phase 1/2 Early January 2018
Phase 1/2 dosing has commenced - noted September 21, 2017 with preliminary data due early January 2018.
LLY
$87.42
+0.92  (+1.06%)
Abemaciclib - MONARCH 1 and 2
Second-line hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer and HR+, HER2- breast cancer
PDUFA priority review
Phase 3 data released March 20, 2017 - PFS primary endpoint met. Noted July 10, 2017 PDUFA under priority review. No exact data released. Assume 6-month review rendering a PDUFA date on or around January 10, 2018.
LPCN
$3.39
+0.03  (+0.89%)
LPCN 1021
Men with low testosterone (Low T)
PDUFA Adcom January 10
CRL issued June 2016. NDA resubmitted with PDUFA orginally scheduled for February 8, 2017 but delayed until May 8, 2017 due to submission of additional data. Advisory Committee meeting January 10, 2018.
ARDM
$5.71
-0.11  (-1.89%)
Linhaliq (Pulmaquin)
Non-cystic fibrosis bronchiectasis (non-CF BE).
PDUFA priority review
PDUFA date under priority review January 26, 2018. Phase 3 data released December 1, 2016. One of two trials met primary endpoint. Advisory Committee Meeting January 11, 2018.
ONCE
$45.31
+0.1  (+0.22%)
Luxturna (voretigene neparvovec)
Inherited retinal dystrophies
PDUFA priority review
PDUFA date January 12, 2018 under priority review. Advisory Committee Meeting October 12, 2017 voted 16-0 in favor of recommending approval.
AXSM
$4.70
+0  (+0%)
AXS-02 CREATE-1
Complex regional pain syndrome (CRPS)
Phase 3 Late December 2017/early January 2018
Initiated July 2015. Interim efficacy analysis due late December 2017 or early January 2018.
AXSM
$4.70
+0  (+0%)
AXS-02 COAST-1
Knee Osteoarthritis Associated with Bone Marrow Lesions
Phase 3 Late December 2017/early January 2018
Phase 3 commenced March 2016. Interim efficacy analysis due late December 2017 or early January 2018.
BLRX
$1.07
+0.02  (+1.98%)
BL-8040 in combination with KEYTRUDA - COMBAT trial
Pancreatic cancer
Phase 2 January 18-20, 2018
Phase 2 initiated September 2016. Partial data to be presented at ASCO 2018 Gastrointestinal Cancers Symposium, January 18-20, 2018. Full data due 2H 2018.
EXEL
$26.28
+0.33  (+1.27%)
XL184 cabozantinib (CELESTIAL)
Advanced hepatocellular cancer (HCC)
Phase 3
Phase 3 data released October 16, 2017 - primary endpoint met. sNDA filing due 1Q 2018. Data to be presented at 2018 ASCO-GI Symposium, January 19, 2018.
SGYP
$1.97
+0.04  (+2.07%)
Trulance (plecanatide)
Constipation-predominant irritable bowel syndrome (IBS-C)
PDUFA
Phase 3 data from first and second trials met primary endpoints - December 9 and 22, 2016. PDUFA date January 24, 2018.
BYSI
$30.22
+1.11  (+3.81%)
Plinabulin (Trial 105)
Prevention of neutropenia
Phase 2/3 January 25-27, 2018
Phase 3 part of trial to commence shortly. Phase 2 data to be presented at the 2018 ASCO-SITC Clinical Immuno-Oncology Symposium Jan. 25-27, 2018.
AAAP
$81.66
+0.07  (+0.08%)
Lutathera
Inoperable progressive midgut NETs
PDUFA
CRL issued December 21, 2016. NDA to be resubmission announced July 27, 2017 with new PDUFA date January 26, 2018.
SCMP
$16.98
+0.23  (+1.34%)
Lubiprostone
Pediatric functional constipation
PDUFA
PDUFA date for sNDA under priority review January 28, 2018.
AST
$2.20
+0  (+0%)
AST-OPC1 SCiSTAR
Cervical spinal cord injury
Phase 1/2 Early 2018
Phase 1/2 six and nine-month data released January 24, 2017. 10 and 20 million cell cohort 6-month top-line data due early 2018.
AXON
$5.46
+0.01  (+0.18%)
Intepirdine
Gait and Balance Impairments in Dementia
Phase 2 January 2018
Phase 2 data due January 2018.
AXON
$5.46
+0.01  (+0.18%)
Intepirdine - HEADWAY-DLB
Dementia with Lewy bodies (DLB)
Phase 2b January 2018
Phase 2b data due January 2018.
AXON
$5.46
+0.01  (+0.18%)
Nelotanserin
Visual hallucinations in subjects with Lewy body dementia
Phase 2 January 2018
Phase 2 preliminary data released February 13, 2017. Primary endpoint hit, secondary endpoints missed. Top-line data due January 2018.
KDMN
$3.61
+0.03  (+0.83%)
KD025
Idiopathic pulmonary fibrosis (IPF)
Phase 2 January 2018
Phase 2 data due January 2018.
XLRN
$35.72
-0.29  (-0.8%)
ACE-083
Facioscapulohumeral muscular dystrophy
Phase 2 January 2018
Phase 2 dosing initiation announced December 22, 2016. Initial data due January 2018.
AMAG
$14.01
+0.21  (+1.52%)
Feraheme
Adults with iron deficiency anemia (IDA)
PDUFA
PDUFA date February 2, 2018 for sNDA filing.
PTLA
$47.32
-0.23  (-0.5%)
Andexanet alfa
Factor Xa inhibitor reversal agent
PDUFA
CRL August 17 2016. New PDUFA date February 2, 2018.
AMGN
$176.90
+1.98  (+1.13%)
XGEVA
Multiple Myeloma
PDUFA
sBLA filing announced April 4, 2017. Acceptance of filing announced June 19, 2017 - PDUFA February 3, 2018.
AVEO
$2.90
-0.04  (-1.2%)
Tivozanib + Opdivo
Renal cell cancer (RCC)
Phase 1/2 February 8-10, 2018
Enrollment of Phase 2 portion of Phase 1/2 trial complete with initial Phase 2 data due at Genitourinary Cancers Symposium February 8-10, 2018.
GILD
$75.29
+0.94  (+1.27%)
Bictegravir/F/TAF
HIV
PDUFA priority review
PDUFA date under priority review February 12, 2018.
AMAG
$14.01
+0.21  (+1.52%)
Makena - auto injector
Reduce the risk of preterm birth in women with a singleton pregnancy
PDUFA
sNDA filing announced April 17, 2017. PDUFA date February 14, 2018. 10-month review despite initial expectations of a 6-month review.
ATRS
$1.97
+0.04  (+1.94%)
Makena - auto injector
Preterm birth
PDUFA
sNDA filing announced April 17, 2017. PDUFA date February 14, 2018. 10-month review despite initial expectations of a 6-month review
PCRX
$44.35
-0.35  (-0.79%)
EXPAREL
Single-dose injection femoral nerve block for total knee arthroplasty surgery
PDUFA Adcom 2/14/18; PDUFA 4/6/18
Phase 3 data released July 25, 2017. Upper extremity met primary endpoint, lower extremity trial missed endpoint. PDUFA date for sNDA filing set for April 6, 2018. Advisory Committee Meeting February 14-15, 2018.
EXEL
$26.28
+0.33  (+1.27%)
Cabozantinib - CABOSUN
First-Line RCC - cancer
PDUFA priority review
Late breaker at ESMO September 10, 2017 showed PFS 8.6 months versus 5.3 months for sunitinib. HR 0.48. PDUFA date under priority review for sNDA February 15, 2018.
KURA
$13.65
-0.1  (-0.73%)
Tipifarnib
Head and neck squamous cell carcinomas (HNSCC)
Phase 2 February 15-17, 2018
Presentation of updated data due February 15-17, 2018 at Multidisciplinary Head and Neck Cancers Symposium.
APRI
$1.68
-0.02  (-1.18%)
Vitaros
Erectile dysfunction
PDUFA
PDUFA date for NDA resubmission February 17, 2018.
KMPH
$3.79
+0.01  (+0.39%)
KP201/APAP
Acute pain.
PDUFA
PDUFA date February 23, 2018 - CRL issued June 13, 2016.
AERI
$60.70
+0.55  (+0.91%)
Rhopressa
Glaucoma
PDUFA
PDUFA date February 28, 2018. Advisory Committee meeting October 13, 2017 voted 9-1 in favor that efficacy outweighs safety risks,
AZN
$33.10
-0.2  (-0.59%)
Lynparza
Breast cancer
PDUFA priority review 1Q 2018
Phase 3 data released February 17, 2016 - primary endpoint met. Late breaker at ASCO June 4, 2017 showed HR of 0.58 (42% reduction of risk of disease progression or death). PDUFA date for sBLA under priority review 1Q 2018.
CRMD
$0.57
+0.01  (+1.94%)
Neutrolin - LOCK-IT 100
Hemodialysis patients with central venous catheters
Phase 3 Early 2018
Phase 3 data due 2H 2018 with interim analysis due early 2018.
IONS
$51.93
+0.37  (+0.71%)
IONIS-HTT Rx
Huntington's Disease
Phase 1/2 Early 2018
Phase 1/2 completion of enrollment noted June 22, 2017. Top-line data due early 2018.
LJPC
$24.09
-0.2  (-0.83%)
LJPC-501
Hypotension
PDUFA priority review
Phase 3 data released February 27, 2016 - primary endpoint hit. Data published May 21, 2017 confirmed primary endpoint was met but with lack of mortality improvement. PDUFA date under priority review February 28, 2018. No Advisory Committee Meeting planned.
MDGL
$78.26
+0.57  (+0.74%)
MGL-3196
Heterozygous familial hypercholesterolemia (HeFH)
Phase 2 Early 2018
Phase 2 top-line data due early 2018.
MRK
$56.33
+0.32  (+0.57%)
Lynparza
Breast cancer
PDUFA priority review 1Q 2018
Phase 3 data released February 17, 2016 - primary endpoint met. Late breaker at ASCO June 4, 2017 showed HR of 0.58 (42% reduction of risk of disease progression or death). PDUFA date for sBLA under priority review 1Q 2018.
MRNS
$8.91
-0.42  (-4.51%)
Ganaxolone
Postpartum depression
Phase 2 Early 2018
Phase 2 data due early 2018.
ONTX
$1.29
-0.1  (-6.95%)
IV Rigosertib - INSPIRE
2nd-line HR-MDS (high risk myelodysplastic syndromes)
Phase 3 Late 2017/early 2018
Phase 3 enrolling. Interim analysis due late 2017 or early 2018. Top-line data due 2H 2018.
RXII
$0.65
+0.02  (+3.14%)
RXI-109-1501
Retinal scarring
Phase 1/2 Early 2018
Phase 2 completion of enrollment announced June 21, 2017. Data due early 2018.
SRNE
$2.50
+0.05  (+2.04%)
ZTlido (lidocaine patch 1.8%)
Pain associated with post-herpetic neuralgia (PHN)
PDUFA
PDUFA date for NDA resubmission February 28, 2017.
VRTX
$143.59
+1.06  (+0.74%)
Tezacaftor (VX-661) / ivacaftor
Cystic fibrosis - Two Copies of the F508del Mutation
PDUFA priority review
Phase 3 data released March 28, 2017 - primary endpoint met. PDUFA date under priority review February 28, 2017.
OTIC
$5.08
+0.07  (+1.5%)
OTIPRIO
Acute otitis externa
PDUFA
Phase 3 trial met primary endpoint - January 5, 2017. PDUFA date for sNDA filing March 2, 2018.
BMY
$62.76
+0.63  (+1.01%)
Opdivo - 4 week applications
PDUFA
PDUFA date March 5, 2018 for sBLA filings across all approved indications.
BIIB
$326.39
+2.84  (+0.87%)
Natalizumab (α4-integrin inhibitor)
Acute ischemic stroke
Phase 2b Early-2018
Phase 2b data due early 2018.
ABIO
$1.37
-0  (-0.06%)
Gencaro - GENETIC-AF trial
Chronic Heart Failure
Phase 2b 1Q 2018
Phase 2b completion of enrollment announced August 16, 2017 - top-line data due late 1Q 2018.
ACOR
$20.70
+0  (+0%)
Tozadenant
Parkinson’s disease (PD)
Phase 3 1Q 2018
Noted November 15, 2017 seven cases of sepsis, five of which were fatal. Phase 3 data due 1Q 2018. However, company noted November 20, 2017 that program will be discontinued.
AIMT
$33.64
-0.23  (-0.68%)
AR101 PALISADE
Peanut Allergy
Phase 3 1Q 2018
Phase 3 initiated January 2016. Enrollment completion announced November 28, 2016. Top-line data due 1Q 2018.
ALT
$1.60
-0.02  (-1.24%)
NasoVAX
Flu vaccine
Phase 1/2 1Q 2018
Phase 2 initial data due 1Q 2018.
ANAB
$89.89
+1.13  (+1.27%)
ANB020
Severe adult peanut allergy
Phase 2a 1Q 2018
Phase 2a data due 1Q 2018.
ANTH
$1.53
+0.04  (+2.68%)
Sollpura - RESULT
Exocrine pancreatic insufficiency
Phase 3 1Q 2018
Phase 3 data due end 1Q 2018.
ARNA
$29.99
-0.29  (-0.96%)
APD371
Pain associated with Crohn's disease
Phase 2 1Q 2018
Phase 2 data due 1Q 2018.
ARNA
$29.99
-0.29  (-0.96%)
Etrasimod
Ulcerative colitis
Phase 2 1Q 2018
Phase 2 data due 1Q 2018.
AVEO
$2.90
-0.04  (-1.2%)
TIVO-3 - tivozanib
Third line treatment of patients with renal cell cancer
Phase 3 1Q 2018
Phase 3 completion of enrollment noted June 20, 2017. Futility analysis released October 6, 2017 - trial to continue as planned. Top-line data due 1Q 2018.
AXON
$5.46
+0.01  (+0.18%)
Nelotanserin
DLB patients experiencing REM Behavior Disorder (RBD)
Phase 2 1Q 2018
Phase 2 data due 1Q 2018.
BHVN
$22.00
+0.07  (+0.31%)
Rimegepant
Migraine
Phase 3 1Q 2018
Phase 3 completion of enrollment noted November 27, 2017 with top-line data due 1Q 2018.
BMY
$62.76
+0.63  (+1.01%)
CM-227 – Opdivo + Yervoy
First-line Non-small cell lung cancer (NSCLC)
Phase 3 Late 2017/Early 2018
Phase 3 interim data due end of 2017 or early in 2018.
CBIO
$9.93
+0  (+0%)
CB 2679d/ ISU304
Hemophilia B
Phase 1/2 Early 2018
Phase 1/2 interim data to be presented at ASH 2017. Top-line data due early 2018.
CDTX
$7.25
+0.15  (+2.11%)
Rezafungin (CD101) IV - STRIVE
Candidemia
Phase 2 1Q 2018
Phase 2 initiated June 2016. Completion of enrollment announced November 28, 2017. Data due 1Q 2018.
CELG
$109.32
+1.08  (+0.99%)
REVLIMID - AUGMENT NHL-007
Relapsed or Refractory Follicular Lymphoma
Phase 3 1Q 2018
Phase 3 enrolling. Data due 1Q 2018.
CLBS
$3.47
+0.04  (+1.07%)
CLBS03
Type 1 diabetes
Phase 2 1Q 2018
Phase 2 top-line data due 1Q 2018.
CLSD
$6.07
+0.13  (+2.18%)
Suprachoroidal CLS-TA - PEACHTREE
Macular edema associated with non-infectious uveitis
Phase 3 1Q 2018
Phase 3 completion of enrollment noted August 7, 2017 with preliminary data due 1Q 2018.
CORT
$16.61
-0.66  (-3.83%)
CORT125134
Cushing’s syndrome
Phase 2 1Q 2018
Phase 2 trial initiated 2Q 2016. Data due 1Q 2018.
CYTK
$8.05
+0.05  (+0.62%)
CK-2127107
Spinal muscular atrophy (SMA)
Phase 2
Phase 2 initiated January 2016. Baseline data from first cohort released June 5, 2017. Cohort 2 enrollment to be completed in 2017. Data due 1Q 2018.
DERM
$26.31
-0.32  (-1.21%)
Olumacostat glasaretil (DRM01)
Acne
Phase 3 1Q 2018
Phase 3 completion of enrollment announced October 5, 2017. Data are due 1Q 2018.
EARS
$0.44
+0.01  (+1.13%)
Keyzilen (AM-101) - TACTT3
Acute inner ear tinnitus
Phase 3 1Q 2018
Phase 3 TACTT3 enrollment resumption announced January 26, 2017 with top-line data 1Q 2018.
ESPR
$58.08
+0.32  (+0.55%)
Bempedoic Acid - 1002-039
Hypercholesterolemia
Phase 2
Phase 2 initiation announced July 26, 2017 - data due 1Q 2018.
EYEG
$1.29
+0.08  (+6.67%)
EGP-437
Ocular inflammation and pain post cataract surgery
Phase 2b 1Q 2018.
Phase 1/2 top-line data released July 2016. Further data released December 5, 2016. Phase 2b commencement of enrollment announced August 1, 2017. Data due 1Q 2018.
FGEN
$41.25
-0.7  (-1.67%)
Pamrevlumab (FG-3019)
Pancreatic cancer
Phase 2
Phase 2 ongoing. Data due late 2017 or 1Q 2018.
FLKS
$3.55
+0  (+0%)
FLX-787 (Aust)
Multiple Sclerosis
Phase 2 1Q 2018
Phase 2 completion of enrollment announced November 28, 2017 with data due late 1Q 2018.
GALE
$0.30
-0.02  (-6.35%)
NeuVax in combination with Herceptin
Breast cancer - 1+/2+
Phase 2b 1Q 2018
Phase 2b completion of enrollment announced September 28, 2017 - with interim efficacy analysis due 1Q 2018.
GERN
$2.00
+0.03  (+1.26%)
Imetelstat - IMbarkStudy
Myelofibrosis
Phase 2
Phase 2 clinical hold lifted Nov 2014. Phase 2 initiated September 2015. Internal review conducted September 2016. Low dose discontinued, high dose enrollment suspended. Further internal data review due 1Q 2018.
GILD
$75.29
+0.94  (+1.27%)
GS-9674
Primary sclerosing cholangitis
Phase 2 1Q 2018
Phase 2 primary endpoint analysis due 1Q 2018.
GILD
$75.29
+0.94  (+1.27%)
GS-9674
Nonalcoholic steatohepatitis (NASH)
Phase 2 1Q 2018
Phase 2 trial to be completed 1Q 2018.
GILD
$75.29
+0.94  (+1.27%)
Entospletinib
Chronic Graft Versus Host Disease (cGVHD)
Phase 2 1Q 2018
Phase 2 interim analysis due 1Q 2018.
GLMD
$9.14
+0.1  (+1.1%)
Aramchol - ARRIVE
HIV-associated lipodystrophy and nonalcoholic fatty liver disease (NAFLD)
Phase 2 1Q 2018
Phase 2 top-line data due 1Q 2018.
GSK
$35.08
-0.17  (-0.47%)
Dolutegravir + lamivudine (GEMINI 1)
HIV
Phase 3
Phase 3 trial commenced August 2016. Data likely due 1Q 2018.
GTHX
$19.62
+0.02  (+0.1%)
Trilaciclib
First-line small-cell lung cancer
Phase 2 1Q 2018
Phase 2a top-line data due 1Q 2018.
GWPH
$129.85
-0.97  (-0.75%)
Epidiolex
Infantile spasms (IS)
Phase 3 1Q 2018
Phase 3 initiated December 2016. Part A data due 1Q 2018.
GWPH
$129.85
-0.97  (-0.75%)
GWP42006 (CBDV)
Epilepsy
Phase 2 1Q 2018
Phase 2 initiated May 2015. Data due 1Q 2018.
IMRN
$5.12
+0  (+0%)
IMM-124E
Nonalcoholic steatohepatitis (NASH)
Phase 2 1Q 2018
Phase 2 interim analysis July 10, 2017 showed no statistical difference with placebo. Top-line data due 1Q 2018.
MBIO
$11.44
-0.24  (-2.06%)
MB-102
Acute myeloid leukemia
Phase 1
Phase 1 data due early 2018.
MBIO
$11.44
-0.24  (-2.06%)
MB-101
Glioblastoma
Phase 1
Phase 1 data due early 2018.
MCRB
$9.89
+0.05  (+0.5%)
SER-262
Primary Clostridium Difficile infection (CDI)
Phase 1b
Phase 1b initiated July 2016. Data due early 2018.
MESO
$5.50
+0.11  (+2.04%)
MPC-150-IM - Class IV
Chronic heart failure (CHF)
Phase 2b
Phase 2b data due 1Q 2018.
MESO
$5.50
+0.11  (+2.04%)
MSC-100-IV
acute graft versus host disease (aGVHD) in children
Phase 3 1Q 2018
Phase 3 enrollment to be completed 4Q 2017. Data due 1Q 2018.
MRK
$56.33
+0.32  (+0.57%)
(MK-3475-189/KEYNOTE-189)
First Line Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
Phase 3 1Q 2018
Phase 3 data likely due 1Q 2018.
MRTX
$17.35
+0.05  (+0.28%)
Mocetinostat and durvalumab
Non-small cell lung cancer (NSCLC)
Phase 2 1Q 2018
Phase 2 data due 1Q 2018.
MYOK
$37.90
-0.7  (-1.82%)
MYK-461 - PIONEER-HCM
Hypertrophic cardiomyopathy (HCM)
Phase 2 1Q 2018
Phase 2 top-line data released August 7, 2017 - primary endpoint met. Data from low dose cohort due 1Q 2018. Phase 3 EXPLORER-HCM trial to be initiated 2Q 2018.
OBSV
$9.80
+0.03  (+0.3%)
OBE001 - IMPLANT2
IVF
Phase 2 1Q 2018
Phase 2 trial did not meet primary endpoint in 2016. Phase 3 completion of patient recruitment announced September 6, 2017. Data due 1Q 2018.
OHRP
$1.57
-0.15  (-8.19%)
OHR-102 (MAKO)
Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase 3
Phase 3 data due early 2018.
PFE
$37.07
+0.6  (+1.65%)
Tanezumab
Chronic low back pain
Phase 3
Phase 3 ongoing. Estimate data due late 2017 or early 2018 using clinicaltrials.gov data.
PFE
$37.07
+0.6  (+1.65%)
Tanezumab
Osteoarthritis
Phase 3
Phase 3 ongoing. Estimate data late 2017 or early 2018 using clinicaltrials.gov data.
PLX
$0.62
-0  (-0.3%)
OPRX-106
Ulcerative Colitis
Phase 2 1Q 2018
Phase 2 completion of enrollment announced November 30, 2017. Data due 1Q 2018.
PTGX
$18.74
+0.51  (+2.79%)
PTG-100
Ulcerative colitis
Phase 2b
Phase 2b initiation announced January 17, 2017. Interim futility analysis early 2018 with top-line data due 2018.
RARE
$44.62
+0.6  (+1.36%)
DTX301
Ornithine Transcarbamylase (OTC) Deficiency
Phase 1/2 Early 2018
Phase 1/2 first cohort of three patients have completed patient dosing with initial data due early 2018.
REGN
$386.05
+2.93  (+0.76%)
Praluent (alirocumab) ODYSSEY OUTCOMES
Cardiovascular events
Phase 3
Phase 3 data due 1Q 2018.
RETA
$25.21
+0.38  (+1.53%)
Bardoxolone methyl - LARIAT
Pulmonary hypertension due to interstitial lung disease - PH-ILD
Phase 2 1Q 2018
Phase 2 enrollment commenced January 2017. Data due 1Q 2018.
RETA
$25.21
+0.38  (+1.53%)
Omaveloxolone - MOTOR
Mitochondrial myopathies (MM)
Phase 2 1Q 2018
Phase 2 initial data due 1Q 2018.
RGLS
$0.92
+0.02  (+2.14%)
RG-012
Renal biopsy study in Alport patients
Phase 1/2 1Q 2018
Phase 1/2 data due 1Q 2018.
SAGE
$159.90
+1.86  (+1.18%)
SAGE-217
Postpartum depression (PPD)
Phase 2 1Q 2018
Phase 2 initiation announced December 4Q 2016. Data due 1Q 2018.
SMMT
$10.23
-0.06  (-0.59%)
Ezutromid
Duchenne muscular dystrophy
Phase 2 1Q 2018
Phase 2 24-week data due 1Q 2018.
SNY
$43.19
+0.1  (+0.23%)
SAR439684 (PD-1)
Cutaneous squamous cell carcinoma
Phase 2
Phase 2 data due 1Q 2018.
SNY
$43.19
+0.1  (+0.23%)
Praluent (alirocumab) ODYSSEY OUTCOMES
Cardiovascular events
Phase 3
Phase 3 data due 1Q 2018.
SPHS
$2.34
-0.01  (-0.43%)
Topsalysin (PRX302)
Localized low to intermediate risk prostate cancer
Phase 2 Late-1Q 2018
Phase 2b initial biopsy data due late 1Q 2018.
SPPI
$18.58
-0.08  (-0.43%)
SPI-2012 (ROLONTIS)
Chemotherapy-Induced Neutropenia
Phase 3 1Q 2018
Phase 3 completion of enrollment announced August 1, 2017 with top-line data due 1Q 2018.
TCON
$3.00
+0.05  (+1.69%)
TRC105 and Inlyta
Renal Cell Carcinoma (RCC) - cancer
Phase 2 Early 2018
Phase 2 initiated Dec 2014. Completion of enrollment announced September 7, 2017. Top-line PFS data due early 2018.
TTPH
$5.78
+0.03  (+0.52%)
Eravacycline (TP-434) - IGNITE3
cUTI - complicated urinary tract infections
Phase 3 1Q 2018
Phase 3 trial did not meet endpoints September 2015. Additional Phase 3 trial initiation announced January 17, 2016. Completion of enrollment announced September 11, 2017. Data due 1Q 2018.
VBLT
$6.65
-0.15  (-2.21%)
VB-111
Recurrent glioblastoma (rGBM) cancer
Phase 3 1Q 2018
Phase 3 completion of enrollment announced January 6, 2017. Top-line data due 1Q 2018.
VICL
$1.78
+0.01  (+0.56%)
ASP0113 Vaccine
Hematopoietic cell transplant recipients
Phase 3 1Q 2018
Phase 3 trial completion announced November 10, 2017. Top-line data due 1Q 2018.
VTVT
$4.33
+0.07  (+1.64%)
Azeliragon - STEADFAST
Mild Alzheimer’s disease
Phase 3 Early 2018
Phase 3 initiated 2Q 2015. Part A enrollment completed September 2016. Part B enrollment completion announced June 1, 2017. Data from Part A due early 2018. Part B due late 2018.
VYGR
$14.35
+0.47  (+3.38%)
VY-AADC01
Advanced Parkinson’s disease
Phase 1b 1Q 2018
Phase 1b trial ongoing. Interim data released December 7, 2016. Positive Cohort 3 data released September 6, 2017. Further updated data due 1Q 2018. Phase 2/3 dosing to commence 2Q 2018.
ZFGN
$3.75
+0.05  (+1.35%)
ZGN-1061
Diabetes
Phase 2 Early 2018
Phase 2 initiation due 3Q 2017. Update due early 2018.
MRK
$56.33
+0.32  (+0.57%)
Keytruda
Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
PDUFA priority review
PDUFA date for sBLA April 3, 2018.
THERF
$5.38
-0.01  (-0.17%)
Ibalizumab
Multi-drug resistant HIV-1
PDUFA
Original PDUFA date January 3, 2018 extended 3 months to April 3. 2018.
CLVS
$63.93
-0.21  (-0.33%)
Rucaparib ARIEL3
Ovarian cancer patients with a BRCA-like mutation
PDUFA priority review
Phase 3 data released June 20 2017 - primary endpoint met. PDUFA date under priority review April 6, 2018.
LLY
$87.42
+0.92  (+1.06%)
Abemaciclib - MONARCH 3
HR+, HER2-locoregionally recurrent or metastatic breast cancer (MBC)
PDUFA priority review
Phase 3 interim analysis April 24, 2017 met primary endpoint. Priority review granted October 12, 2017. PDUFA date not announced - estimate April 12, 2017 using 6-month timeline.
BMY
$62.76
+0.63  (+1.01%)
CM-214 – Opdivo + Yervoy
First-line Renal cell carcinoma (RCC)
PDUFA priority review
Phase 3 trial stopped early due to clear efficacy - trial met co-primary endpoint. HR 0.63. PDUFA under priority review April 16, 2018.
RARE
$44.62
+0.6  (+1.36%)
KRN23 Burosumab
X-Linked Hypophosphatemia (XLH)
PDUFA priority review
Phase 3 data released April 18, 2017 - primary endpoint met. PDUFA date under priority review April 17, 2018. Advisory Committee Meeting not expected.
RIGL
$3.50
-0.08  (-2.11%)
Fostamatinib
Immune Thrombocytopenic Purpura (ITP)
PDUFA
Phase 3 data from the first trial released August 30 2016. Primary endpoint met. Data from second trial did not meet the primary endpoint. PDUFA date April 17, 2018. Noted October 2, 2017 that no Advisory Committee meeting is planned.
ABBV
$97.47
+1.17  (+1.21%)
Elagolix
Endometriosis
PDUFA priority review
First Phase 3 trial met both co-primary endpoints - Jan 2015. Data from second Phase 3 released February 2016 also met endpoints. NDA filing announced September 6, 2017. Priority review announced October 27, 2017. Exact PDUFA date not announced. Estimate April 27, 2017 based on 6-month review.
NBIX
$70.50
+0.08  (+0.11%)
Elagolix
Endometriosis
PDUFA priority review
First Phase 3 trial met both co-primary endpoints - Jan 2015. Data from second Phase 3 released February 2016 also met endpoints. NDA filing announced September 6, 2017. Priority review announced October 27, 2017. Exact PDUFA date not announced. Estimate April 27, 2017 based on 6-month review.
ALKS
$51.42
-0.15  (-0.28%)
ALKS 3831 - ENLIGHTEN-2
Schizophrenia
Phase 3 Fall 2018
Pivotal trial initiated February 2016. Data due fall of 2018.
AMGN
$176.90
+1.98  (+1.13%)
KYPROLIS (ENDEAVOR)
Relapsed Multiple Myeloma
PDUFA
Phase 3 trial met PFS endpoint - March 2015. Announced February 28, 2017 that interim analysis met secondary endpoint of overall survival (OS). PDUFA date for sNDA April 30, 2018.
KPTI
$9.20
-0.05  (-0.55%)
Selinexor - STORM
Quadruple Refractory Multiple Myeloma
Phase 2b April 2018
Phase 2b STORM Study Expansion data due April 2018.
NBRV
$5.23
-0.12  (-2.25%)
Lefamulin - LEAP 2
Moderate to severe Community Acquired Bacterial Pneumonia (CABP)
Phase 3 Spring 2018
Phase 3 completion of enrollment announced December 4, 2017 with data due spring 2018.
AMGN
$176.90
+1.98  (+1.13%)
Erenumab
Migraine
PDUFA
Phase 3 trial met primary endpoint September 2016. PDUFA date May 17, 2018.
NVS
$84.58
+0.11  (+0.13%)
Erenumab
Migraine
PDUFA
Phase 3 trial met primary endpoint September 2016. PDUFA date May 17, 2018.
REPH
$9.57
+0  (+0%)
Intravenous (IV) meloxicam
Acute pain following bunionectomy surgery
PDUFA
Phase 3 data from second trial released November 28, 2016. Primary endpoint met. NDA filing announced July 31, 2017. PDUFA date May 26, 2018.
AMGN
$176.90
+1.98  (+1.13%)
Prolia (denosumab)
Glucocorticoid-induced osteoporosis (GIOP)
PDUFA
PDUFA date for sBLA filing May 28, 2017.
KTOV
$2.25
+0.11  (+5.19%)
KIT-302
Osteoarthritis and Hypertension
PDUFA
PDUFA date May 31, 2018.
PFE
$37.07
+0.6  (+1.65%)
Xeljanz
Ulcerative colitis
PDUFA
sNDA acceptance announced July 13, 2017. 3-month extension announced December 13, 2017.PDUFA date not given. Estimate June 13 using 8 (+3) month timeline.
VRX
$20.03
+0.34  (+1.75%)
IDP-118
Psoriasis
PDUFA
PDUFA date June 18, 2018.
ABBV
$97.47
+1.17  (+1.21%)
Elagolix
Uterine Fibroids
Phase 3 2018
Phase 3 initiated January 2016. Data due 2018.
ABBV
$97.47
+1.17  (+1.21%)
Rova-T (TRINITY)
Third-line Small Cell Lung Cancer
Phase 2 2Q 2018
Phase 2 pivotal data 2Q 2018.
ACRS
$24.85
+0.13  (+0.52%)
ATI-50002
Patchy alopecia areata
Phase 2 1H 2018
Phase 2 trial to be initiated October 2017. Data due 1H 2018.
AGN
$173.10
+2.15  (+1.26%)
ATOGEPANT
Prophylaxis (migraine)
Phase 2b
Phase 2b top-line data due 1H 2018.
AGN
$173.10
+2.15  (+1.26%)
UBROGEPANT
Acute (migraine)
Phase 3
Phase 3 initiated July 2016. Data due 1H 2018.
AGN
$173.10
+2.15  (+1.26%)
ESMYA (ulipristal acetate)
Uterine Fibroids
PDUFA 1H 2018
Phase 3 data released January 18, 2017 - endpoints met. PDUFA date 1H 2018 - exact date not provided.
ALRN
$9.79
-0.29  (-2.79%)
ALRN-6924
Peripheral T-cell lymphoma (PTCL)
Phase 2a 1H 2018
Phase 2a interim data due 1H 2018.
AMGN
$176.90
+1.98  (+1.13%)
ABP 798
RITUXAN biosimilar - non-Hodgkin lymphoma
Phase 3
Phase 3 enrolling. Estimate data 1H 2018 using clinicaltrials.gov data.
ANAB
$89.89
+1.13  (+1.27%)
ANB020
Severe adult eosinophilic asthma
Phase 2a
Phase 2a data due 2Q 2018.
ANIK
$53.00
+0.23  (+0.43%)
Cingal
Osteoarthritis
Phase 3 1H 2018
Phase 3 completion of enrollment announced October 25, 2017. Trial to be completed 1H 2018.
ARGS
$0.15
+0  (+2.09%)
rocapuldencel-T (AGS-003) ADAPT Trial
Metastatic renal cell carcinoma (mRCC)
Phase 3 1H 2018
Phase 3 trial recommended be discontinued for futility - February 22, 2016. Noted August 9, 2017 that it intends to continue the ADAPT trial until at least the pre-specified number of 290 events occurs. Noted further on November 9, 2017 that it intends to request to the FDA to increase the number beyond 290. Interim analysis 1H 2018.
ARRY
$11.04
-0.08  (-0.72%)
Binimetinib - COLUMBUS
BRAF mutant melanoma cancer
PDUFA
Phase 3 data released September 26, 2016 met primary endpoint. PDUFA date June 30, 2018 - no Adcom anticipated.
AVIR
$0.59
-0  (-0.82%)
BTA074 5% topical gel
Condyloma
Phase 2 2Q 2018
Phase 2 completion of enrollment announced November 29, 2017 with data due 2Q 2018.
AXSM
$4.70
+0  (+0%)
AXS-05 STRIDE-1
Treatment resistant depression
Phase 3 1H 2018
Phase 3 initiated March 2016. Top-line data due 1H 2018.
AZN
$33.10
-0.2  (-0.59%)
Selumetinib - ASTRA
Thyroid cancer
Phase 3 1H 2018
Phase 3 data due 1H 2018.
AZN
$33.10
-0.2  (-0.59%)
PT010
Chronic obstructive pulmonary disease (COPD)
Phase 3 1H 2018
Phase 3 data due 1H 2018.
AZN
$33.10
-0.2  (-0.59%)
Lynparza
First-line ovarian cancer
Phase 3 1H 2018
Phase 3 data due 1H 2018.
AZN
$33.10
-0.2  (-0.59%)
Durvalumab +/- tremelimumab (MYSTIC)
Lung cancer
Phase 3
Phase 3 data released July 27, 2017 - primary endpoint not met. Overall survival data due 1H 2018.
AZN
$33.10
-0.2  (-0.59%)
Durvalumab +/- tremelimumab (KESTREL)
Head & neck cancer
Phase 3 1H 2018
Phase 3 data due 1H 2018.
AZN
$33.10
-0.2  (-0.59%)
Durvalumab +/- tremelimumab (EAGLE)
Head & neck cancer
Phase 3 1H 2018
Phase 3 data due 1H 2018.
AZN
$33.10
-0.2  (-0.59%)
Durvalumab +/- tremelimumab (ARCTIC)
Lung cancer
Phase 3 1H 2018
Phase 3 data 1H 2018.
BMY
$62.76
+0.63  (+1.01%)
CM-651 – Opdivo + Yervoy
First-line Head and Neck Cancer
Phase 3
Phase 3 data due 1H 2018.
BMY
$62.76
+0.63  (+1.01%)
CM-511 – Opdivo + Yervoy
First-line Melanoma
Phase 3 1H 2018
Phase 3 data due 1H 2018.
BMY
$62.76
+0.63  (+1.01%)
CM-451 – Opdivo + Yervoy
First-line Small cell lung cancer (SCLC)
Phase 3
Phase 3 data due 1H 2018.
BMY
$62.76
+0.63  (+1.01%)
CM-331– Opdivo
Second-line Small cell lung cancer (SCLC)
Phase 3
Phase 3 data due 1H 2018.
BMY
$62.76
+0.63  (+1.01%)
CM-548 - Opdivo+SOC
First-line Glioblastoma (GBM) cancer
Phase 2
Phase 2 data due 1H 2018.
BOLD
$28.65
-0.21  (-0.73%)
AT342 - VALENS
Crigler-Najjar
Phase 1/2 2Q 2018
Phase 1/2 preliminary data due 2Q 2018.
CLDX
$2.93
+0.01  (+0.34%)
Glembatumumab vedotin
Metastatic triple negative breast cancers that overexpress gpNMB
Phase 2b 2Q 2018
Phase 2b completion of enrollment announced August 23, 2017. Data 2Q 2018.
CLSD
$6.07
+0.13  (+2.18%)
Suprachoroidal CLS-TA - TYBEE
Diabetic Macula Edema (DME)
Phase 2 2Q 2018
Phase 2 completion of enrollment announced October 24, 2017 with preliminary data 2Q 2018.
CLSD
$6.07
+0.13  (+2.18%)
Suprachoroidal CLS-TA - HULK
Diabetic macular edema (DME)
Phase 1/2 2Q 2018
Phase 1/2 enrollment completion announced April 20, 2017. Preliminary data due 2Q 2018.
CNAT
$4.14
+0.05  (+1.22%)
Emricasan
Liver fibrosis post-orthotopic liver transplant due to Hepatitis C virus infection (HCV-POLT)
Phase 2b 1H 2018
Phase 2b initiated May 2014. Topline data due 1H 2018.
CORI
$10.99
-0.3  (-2.66%)
Corplex Donepezil
Alzheimer's disease
Phase 3 1H 2018
Pilot bioequivalence data due released May 11, 2017. Pivotal trial commenced fall of 2017 with preliminary data due 1H 2018.
CPRX
$4.11
+0.01  (+0.12%)
Firdapse
Congenital Myasthenic Syndromes (CMS)
Phase 3 1H 2018
Phase 3 data due 1H 2018.
CTIC
$2.48
-0.03  (-1.2%)
PIXUVRI - PIX306 Trial
B-cell non-Hodgkin lymphoma
Phase 3
Phase 3 data due 1H 2018. Noted August 2, 2017 that enrollment has completed.
DBVT
$21.49
-0.21  (-0.97%)
Viaskin Milk
Cow’s milk protein allergy (CMPA)
Phase 2b 1H 2018
Phase 2b data due 1H 2018.
ESPR
$58.08
+0.32  (+0.55%)
Bempedoic acid - CLEAR LDL-C Lowering Program 1002-046, 1002-047 and 1002-048
Hypercholesterolemia - statin intolerance
Phase 3
Phase 3 initiation of efficacy trials announced January 8, 2017. Data due 2Q and 3Q 2018.
ESPR
$58.08
+0.32  (+0.55%)
Bempedoic acid (ETC-1002-040) - Clear Harmony
Hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins
Phase 3
Phase 3 long-term safety and tolerability trial initiated January 2016. Completion of enrollment announced January 25, 2017. Top-line results due 2Q 2018.
EXEL
$26.28
+0.33  (+1.27%)
IMblaze370 - cobimetinib and atezolizumab
Third-line advanced or metastatic colorectal cancer
Phase 3 1H 2018
Phase 3 enrollment completed 1Q 2017. Data due 1H 2018.
EYEG
$1.29
+0.08  (+6.67%)
EGP-437
Non-infectious anterior uveitis
Phase 3 2Q 2018
Phase 3 top-line data due 2Q 2018.
FBIO
$3.50
-0.02  (-0.57%)
CEVA101
Severe Traumatic Brain Injury
Phase 2
Phase 2 data in children due 1H 2018.
FBIO
$3.50
-0.02  (-0.57%)
Pepvax vaccine
Cytomegalovirus (CMV)
Phase 2
Phase 2 data due 1H 2018.
FBIO
$3.50
-0.02  (-0.57%)
IV Tramadol
Post-operative Pain
Phase 3 2Q 2018
Phase 3 initiation announced September 27, 2017 with data due 2Q 2018.
FLKS
$3.55
+0  (+0%)
FLX-787
Amyotrophic lateral sclerosis (ALS)
Phase 2
Phase 2 initiated September 2016. Readout due 2017/18.
GEMP
$8.02
+0.01  (+0.12%)
Gemcabene - INDIGO-1
Severe Hypertriglyceridemia (SHTG)
Phase 2b 2Q 2018
Phase 2b data due 2Q 2018.
GILD
$75.29
+0.94  (+1.27%)
Filgotinib - EQUATOR
Psoriatic arthritis
Phase 2 2Q 2018
Phase 2 initiation announced April 4, 2017. Trial to be completed 2Q 2018.
GILD
$75.29
+0.94  (+1.27%)
Selonsertib (GS-4997)
Alcoholic Hepatitis
Phase 2 2Q 2018
Phase 2 trial to be completed 2Q 2018.
GLMD
$9.14
+0.1  (+1.1%)
Aramchol - ARREST
Non-Alcoholic Steatohepatitis (NASH)
Phase 2b 2Q 2018
Phase 2b data due 2Q 2018.
GLPG
$91.21
+6.73  (+7.96%)
Filgotinib - TORTUGA
Ankylosing spondylitis
Phase 2 2Q 2018
Phase 2 initiation announced April 4, 2017. Trial to be completed 2Q 2018.
GLPG
$91.21
+6.73  (+7.96%)
Filgotinib - EQUATOR
Psoriatic arthritis
Phase 2 2Q 2018
Phase 2 initiation announced April 4, 2017. Trial to be completed 2Q 2018.
GTHX
$19.62
+0.02  (+0.1%)
G1T38 plus Faslodex
ER+ breast cancer
Phase 1b 2Q 2018
Phase 1b preliminary data due 2Q 2018.
IDRA
$1.93
-0.03  (-1.29%)
IMO-8400
Dermatomyositis
Phase 2 2Q 2018
Phase 2 initiated November 2015. Enrollment to be completed by the end of 2017 with data due 2Q 2018.
INCY
$95.29
-0.68  (-0.71%)
Epacadostat with Keytruda - ECHO-301
Cancer - first-line metastatic melanoma.
Phase 3 1H 2018
Phase 3 initiated June 2016. Initial data due 1H 2018.
INCY
$95.29
-0.68  (-0.71%)
Ruxolitinib - REACH 1
Graft versus host disease
Phase 3 1H 2018
Phase 2 pivotal trial dosing initiation announced December 30, 2016. Data due 1H 2018.
JNCE
$12.98
+0.17  (+1.32%)
JTX-2011
Solid tumors - Cancer
Phase 1/2
Phase 1/2 trial initiated September 2017.Phase 2 arm initiation announced April 21, 2017. Efficacy data due 1H 2018.
JNJ
$142.55
+0.9  (+0.63%)
Esketamine
Treatment resistant depression
Phase 3
Phase 3 ongoing. Data and regulatory filings likely due 2018.
KURA
$13.65
-0.1  (-0.73%)
Tipifarnib
Lower risk myelodysplastic syndromes (MDS) - cancer
Phase 2
Phase 2 top-line data due 1H 2018.
MACK
$10.39
+0.21  (+2.06%)
MM-141 - CARRIE
Cancer - front line pancreatic cancer
Phase 2
Phase 2 completion of enrollment announced June 19, 2017. Data due 1H 2018.
MDWD
$4.65
-0.05  (-1.07%)
NexoBrid
Severe burns
Phase 3
Phase 3 initiated mid April 2015. Data due 1H 2018.
MEIP
$2.12
+0  (+0%)
Pracinostat in combination with Vidaza
High-risk Myelodysplastic Syndrome (MDS)
Phase 2 1H 2018
Phase 2 commencement of dosing announced June 14, 2017 - data from first stage due 1H 2018.
MGNX
$19.24
+0.22  (+1.15%)
Margetuximab in combination with pembrolizumab
Gastric cancer
Phase 2 1H 2018
Phase 2 data due 1H 2018.
MTNB
$1.47
-0.01  (-0.68%)
MAT2501
Non-tuberculous mycobacterium (NTM)
Phase 2
Phase 2 trial to be initiated 2H 2018. Data from PK/tolerability trial due 2Q 2018.
NBIX
$70.50
+0.08  (+0.11%)
Elagolix
Uterine Fibroids
Phase 3 2018
Phase 3 initiated by partner Abbvie in January 2016. Data due 2018.
NVS
$84.58
+0.11  (+0.13%)
LEE011: MONALEESA-3
Breast cancer - (post-menopausal)
Phase 3 2Q 2018
Phase 3 trial completion 4Q 2017, publication due 2Q 2018.
PBYI
$99.48
-0.23  (-0.23%)
Neratinib
Third-line HER2-positive metastatic breast cancer
Phase 3 1H 2018
Phase 3 data due 1H 2018.
PFNX
$2.23
+0  (+0%)
PF708 and Forteo
Osteoporosis
Phase 3 1H 2018
Top-line immunogenicity data due 1H 2018.
PRTA
$36.64
+0.05  (+0.13%)
NEOD001 PRONTO
Previously-treated patients with AL amyloidosis and persistent cardiac dysfunction
Phase 2b 2Q 2018
Phase 2b data due 2Q 2018.
PSTI
$1.40
-0.02  (-1.41%)
PLX-PAD (stem cells)
Intermittent claudication, or IC
Phase 2 1H 2018
Phase 2 put on clinical hold Jun 2013. Lifted Sept 2013. Enrollment completed May 2016. Data are due 1H 2018.
RNN
$1.93
-0.01  (-0.52%)
RX-3117 in combination with Abraxane
First-line pancreatic cancer
Phase 2a
Phase 2 data due 2Q 2018.
RXDX
$15.43
-0.12  (-0.81%)
RXDX-105
Solid tumors - cancer
Phase 1b 1H 2018
Phase 1b data update 1H 2018.
RYTM
$27.28
-0.76  (-2.72%)
Setmelanotide
POMC Epigenetic Disorders
Phase 2 1H 2018
Phase 2 data due 1H 2018.
RYTM
$27.28
-0.76  (-2.72%)
Setmelanotide
Alstrom Syndrome
Phase 2 1H 2018
Phase 2 data due 1H 2018.
RYTM
$27.28
-0.76  (-2.72%)
Setmelanotide
POMC Heterozygous Deficiency Obesity
Phase 2 1H 2018
Phase 2 data due 1H 2018.
SBBP
$6.25
+0.1  (+1.62%)
COR-003 (levoketoconazole) - SONICS
Endogenous Cushing’s syndrome
Phase 3 2Q 2018
Phase 3 completion of enrollment announced June 27, 2017 with top-line data due 2Q 2018.
SGMO
$16.25
-0.15  (-0.92%)
SB-525 cDNA gene therapy
Hemophilia A
Phase 1/2 1H 2018
Phase 1/2 enrolling. Data due 1H 2018.
SGMO
$16.25
-0.15  (-0.92%)
SB-318
MPS Type 1
Phase 1/2 1H 2018
Phase 1/2 data due 1H 2018.
SGMO
$16.25
-0.15  (-0.92%)
SB-FIX
Hemophilia B
Phase 1/2 1H 2018
Phase 1/2 data due 1H 2018.
SGMO
$16.25
-0.15  (-0.92%)
SB-913 - CHAMPIONS
MPS Type 2
Phase 1/2 1H 2018
Phase 1/2 commencement of dosing announced November 15, 2017 with data due 1H 2018.
SNDX
$8.61
-0.39  (-4.34%)
Entinostat plus Keytruda - ENCORE 601
Recurrent non-small cell lung cancer (NSCLC)
Phase 1/2 1H 2018
Phase 2 trial to advance to second stage of trial - noted May 16, 2017. Updated data due 1H 2018.
SNDX
$8.61
-0.39  (-4.34%)
E2112
HR+, HER2- breast cancer
Phase 3 1H 2018
Phase 3 PFS data due by the end of 1H 2018.
SNGX
$1.93
+0.02  (+0.82%)
SGX301 (synthetic hypericin)
Cutaneous T-Cell Lymphoma (CTCL) cancer
Phase 3
Phase 3 data due 1H 2018.
SVRA
$15.15
+0.14  (+0.89%)
Aironite - INDIE
Pulmonary hypertension (PH)
Phase 2 1H 2018.
Phase 2 completion of enrollment announced October 18, 2017. Data due 1H 2018.
TBPH
$27.66
+0.34  (+1.24%)
TD-9855
nOH
Phase 2a 1H 2018
Phase 2a data due 1H 2018.
TCON
$3.00
+0.05  (+1.69%)
TRC253
Prostate cancer
Phase 1/2 1H 2018
Phase 1/2 dosing commenced May 24, 2017. Completion of dose escalation phase due 1H 2018.
TCON
$3.00
+0.05  (+1.69%)
TRC105 and Nexavar
Hepatocellular carcinoma (HCC) - cancer
Phase 2 1H 2018
Phase 2 dosing initiated May 2016 with data due 1H 2018.
TGTX
$8.33
+0.07  (+0.9%)
TG-1101 and TGR-1202 - UNITY-CLL study
Chronic Lymphocytic Leukemia (CLL) and non-Hodgkin's Lymphoma (NHL)
Phase 3 2Q 2018
Phase 3 completion of full enrollment announced October 16, 2017 with top-line data due 2Q 2018.
TNXP
$3.58
-0.02  (-0.56%)
TNX-102 SL
Post-traumatic stress disorder (PTSD)
Phase 3 1H 2018
Initiation of first of two Phase 3 trials announced March 28, 2017 in military-related PTSD 1Q 2017. Interim analysis due 1H 2018 with top-line data due 2H 2018.
TOCA
$11.52
-0.36  (-3.04%)
Toca 511 & Toca FC
Recurrent brain cancer
Phase 2/3
Data from Phase 2 portion are due 1H 2018.
TPIV
$3.26
-0.03  (-0.89%)
TPIV200
Second line triple-negative breast cancer (TNBC)
Phase 2 1H 2018
Phase 2 enrollment commenced - noted December 13, 2017. Interim data due 1H 2018.
TSRO
$80.24
-3.63  (-4.33%)
Niraparib and Keytruda (TOPACIO)
Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 1H 2018
Phase 1/2 enrolling. Initial data presented at ASCO investor event. ORR 4/13 patients. Further data due 1H 2018.
URGN
$37.30
+0.2  (+0.53%)
MitoGel - OLYMPUS
Upper tract urothelial carcinoma (UTUC)
Phase 3 2Q 2018
Phase 3 enrollment commenced April 3, 2017. Top-line data due 2Q 2018.
VICL
$1.78
+0.01  (+0.56%)
VCL-HB01 HSV-2 Therapeutic Vaccine
Genital Herpes in Adults
Phase 2 2Q 2018
Phase 2 trial initiated September 2016. Enrollment completion announced April 19, 2017 with data due 2Q 2018.
VKTX
$3.80
+0.06  (+1.6%)
VK2809
Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease
Phase 2 1H 2018
Phase 2 trial to be completed 1H 2018.
VTGN
$1.09
-0.01  (-0.91%)
AV-101
Monotherapy Treatment Major Depressive Disorder
Phase 2 1H 2018
Phase 2 top-line data due 1H 2018.
ZGNX
$37.20
-0.56  (-1.46%)
ZX008 - Study 1504
Dravet syndrom
Phase 3 2Q 2018
Phase 3 data due 2Q 2018.
DRRX
$1.02
+0.03  (+2.85%)
RBP-7000
Schizophrenia
PDUFA PDUFA date July 28, 2017.
PDUFA date July 28, 2017.
INSY
$5.95
-0.08  (-1.33%)
Buprenorphine
Moderate to severe postoperative pain after bunionectomy
PDUFA
Phase 3 data met primary endpoints - August 2016. PDUFA date July 28, 2018. Data to be submitted 1Q 2018 from safety trial, which might impact on PDUFA date (i.e. possible extension).
ALNY
$125.79
+2.13  (+1.72%)
Givosiran
Acute hepatic porphyrias
Phase 3 Mid-2018
Phase 3 trial initation announced November 7, 2017 with interim analysis data available in mid-2018.
BLRX
$1.07
+0.02  (+1.98%)
BL-8040
Stem-cell mobilization for allogeneic transplantation
Phase 2 Mid-2018
Phase 2 top-line data due by mid-2018.
BYSI
$30.22
+1.11  (+3.81%)
Plinabulin (Trial 106)
Prevention of neutropenia
Phase 2/3 Mid-2018
First data due mid-2018.
CELG
$109.32
+1.08  (+0.99%)
Luspatercept - BELIEVE
b -thalassemia
Phase 3
Phase 3 enrollment completion announced June 1, 2017 with data due mid-2018.
CELG
$109.32
+1.08  (+0.99%)
Luspatercept - MEDALIST
Myelodysplastic syndromes (MDS) cancer
Phase 3 Mid-2018
Phase 3 enrollment completion announced June 1, 2017 with data due mid-2018.
EBIO
$0.68
+0.02  (+3.64%)
Vicinium
Non-muscle invasive bladder cancer (NMIBC)
Phase 3 Mid-2018
Phase 3 top-line data (3-month) due mid-2018 and 12-month data due 2Q 2019.
FOMX
$5.95
+0.01  (+0.16%)
FMX103
Papulopustular rosacea
Phase 3 Mid-2018
Phase 2 top-line data released September 12, 2016. Endpoints met. Phase 3 top-line data due mid-2018.
FOMX
$5.95
+0.01  (+0.16%)
FMX101 - FX2017-22
Acne
Phase 3 Mid-2018
Phase 3 data released March 27, 2017 - three of four primary endpoints met across two trials. Third Phase 3 trial data due mid-2018.
GNMX
$1.21
+0.03  (+2.54%)
AEVI-001 (NFC-1)
ADHD - 9-Gene subset
Phase 2 Mid-2018
Phase 2 data due mid-2018.
GNMX
$1.21
+0.03  (+2.54%)
AEVI-002 (Anti-LIGHT mAb)
Pediatric onset Crohn's disease
Phase 1/2 Mid-2018
Phase 1/2 data due mid-2018.
LLY
$87.42
+0.92  (+1.06%)
Ramucirumab
Second-line bladder cancer
Phase 3
Phase 3 PFS data released May 31, 2017 - primary endpoint met. Final OS results are currently expected in mid-2018.
MRTX
$17.35
+0.05  (+0.28%)
Sitravatinib plus nivolumab
Non-small cell lung cancer (NSCLC)
Phase 2 Mid-2018
Phase 2 data due by mid-2018.
OBSV
$9.80
+0.03  (+0.3%)
OBE2109 - EDELWEISS
Endometriosis
Phase 2b Mid-2018
Phase 2b data due mid-2018.
RDHL
$4.85
+0.05  (+1.04%)
RHB-104 MAP US
Crohn’s disease
Phase 3 Mid-2018
Phase 3 enrollment completion announced November 9, 2017 with data due mid-2018.
SCYX
$2.32
+0.1  (+4.44%)
SCY-078 - oral
Vulvovaginal candidiasis (VVC)
Phase 2 Mid-2018
Phase 2 initiation of dosing announced August 3, 2017 - data due mid-2018.
SNSS
$3.19
-0.01  (-0.32%)
SNS-062
Advanced B-Cell Malignancies
Phase 1/2 Mid-2018
Phase 1/2 initiation of dosing announced July 18, 2017. Interim data due mid-2018.
VNDA
$14.15
+0.1  (+0.71%)
Tradipitant
Gastroparesis
Phase 2 Mid-2018
Phase 2 data due mid-2018.
XLRN
$35.72
-0.29  (-0.8%)
Luspatercept - MEDALIST
Myelodysplastic syndromes (MDS) cancer
Phase 3 Mid-2018
Phase 3 enrollment completion announced June 1, 2017 with data due mid-2018.
XLRN
$35.72
-0.29  (-0.8%)
Luspatercept - BELIEVE
b -thalassemia
Phase 3 Mid-2018
Phase 3 enrollment completion announced June 1, 2017 with data due mid-2018.
REGN
$386.05
+2.93  (+0.76%)
EYLEA
Wet AMD
PDUFA
PDUFA date for sBLA August 11, 2018 - 12-week dosing.
AKCA
$19.52
+0.36  (+1.9%)
Volanesorsen - APPROACH
Familial chylomicronemia syndrome (FCS)
PDUFA
PDUFA date August 30, 2017.
ALXN
$114.23
+1.13  (+1%)
Eculizumab
Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD)
Phase 3 Mid-2018
Phase 3 enrollment to be completed in 2017 with data due mid-2018.
AGLE
$5.18
-0.04  (-0.77%)
AEB1102
Arginase I deficiency
Phase 1/2 3Q 2018
Phase 1/2 top-line data due 3Q 2018.
AGTC
$3.60
-0.03  (-0.69%)
rAAV-hRS1
X-linked retinoschisis (XLRS)
Phase 1/2
Phase 1/2 completion of enrollment due 1Q 2018 with data due after the last patient has been followed for six months (est 3Q 2018).
AMRN
$3.31
+0.03  (+0.91%)
Vascepa REDUCE-IT outcomes trial
High Triglycerides With Mixed Dyslipidemia
3Q 2018
Interim analysis announced September 12, 2016 - trial to proceed. Second interim analysis August 14, 2017 also recommended trial to continue. Final data due 3Q 2018.
AQXP
$10.72
+0.46  (+4.48%)
AQX-1125 LEADERSHIP
Bladder pain syndrome/interstitial cystitis (BPS/IC).
Phase 3
Phase 2 trial did not meet endpoints - June 2015 but postive secondary endpoint data - August 2015. Phase 3 trial commenced September 2016. Data due 3Q 2018.
FLKS
$3.55
+0  (+0%)
FLX-787 - COMMEND US trial
Amyotrophic lateral sclerosis (ALS)
Phase 2 3Q 2018
Phase 2 start noted August 1, 2017. Data due 3Q 2018.
GILD
$75.29
+0.94  (+1.27%)
F/TAF (Descovy)
Pre-exposure prophylaxis
Phase 3 3Q 2018
Phase 3 trial to be completed 3Q 2018.
HSGX
$1.88
+0.07  (+3.86%)
NeoCart
Cartilage defects in the knee
Phase 3
Phase 3 completion of enrollment announced June 27, 2017. Top-line data and potential BLA filing 3Q 2018.
RGLS
$0.92
+0.02  (+2.14%)
RG-012 - HERA
Alport Syndrome
Phase 2 3Q 2018
Phase 2 interim data due 3Q 2018.
VTL
$5.73
+0.23  (+4.09%)
VTI-308
Alcohol-induced liver decompensation, or AILD
Phase 3 3Q 2018
Phase 3 VTI-208 trial failed. New VTI-308 trial initiated May 2016. Data due 3Q 2018.
CNCE
$27.27
+1.01  (+3.84%)
AVP-786
Agitation in patients with Alzheimer's disease
Phase 3
Phase 3 initiated December 2015. Trial to be completed 3Q 2018
LLY
$87.42
+0.92  (+1.06%)
Galcanezumab - EVOLVE-1, EVOLVE-2 and REGAIN
Migraine prevention
PDUFA
BLA filing acceptance announced December 11, 2017. No PDUFA data supplied - estimate October 10, 2018.
ABBV
$97.47
+1.17  (+1.21%)
ABT-494 - SELECT-COMPARE
Rheumatoid arthritis
Phase 3 2018
Phase 3 data due 2018.
ABBV
$97.47
+1.17  (+1.21%)
Imbruvica - PHOENIX
First-line Diffuse large B-cell lymphoma (DLBCL)
Phase 3 2018
Phase 3 data possibly due 2018.
ABUS
$4.43
-0.12  (-2.75%)
ARB-1467, tenofovir, and pegylated interferon
Hepatitis B (HBV)
Phase 2 2H 2018
Phase 2 interim data due 2H 2018 with full data due 2019.
ACIU
$12.67
+0.37  (+2.99%)
ACI-24 (anti-Abeta vaccine)
Alzheimer's disease-like characteristics in individuals with Down syndrome
Phase 1/2 2018
Phase 1/2 completion of recruitment of low-dose cohort noted September 12, 2017. Interim data due 2018.
ACRS
$24.85
+0.13  (+0.52%)
ATI-50001
Alopecia totalis and alopecia universalis
Phase 2 YE 2018
Phase 2 data due by the end of 2018.
ACRS
$24.85
+0.13  (+0.52%)
A-101
Common warts (verruca vulgaris)
Phase 2b 2H 2018
Phase 2 data released August 2016. Phase 2b trial initiation announced June 29, 2017. Top-line data due 2H 2018.
ADVM
$3.15
+0.05  (+1.61%)
ADVM-043
Alpha-1 Antitrypsin (A1AT) Deficiency
Phase 1/2 2H 2018
Phase 1/2 commencement of enrollment announced December 5, 2017 with preliminary data due 2H 2018.
ADXS
$3.07
+0.02  (+0.65%)
ADXS-PSA and Keytruda
Castrate-resistant prostate cancer
Phase 1/2 2018
Completed the first two dose-escalation cohorts and launched the third dose-escalation cohort in April 2016. Part B combination portion of trial commenced October 2016. Preliminary data due 2018.
AGN
$173.10
+2.15  (+1.26%)
Brazikumab
Crohn's disease
Phase 2b
Phase 2b data due 2018.
AGN
$173.10
+2.15  (+1.26%)
Cariprazine
Major depressive disorder (MDD)
Phase 3
Phase 3 data due 2H 2018.
AGN
$173.10
+2.15  (+1.26%)
ABICIPAR
Age-related macular degeneration (AMD)
Phase 3
Phase 3 data due 2H 2018.
AKBA
$14.94
+0.1  (+0.67%)
Vadadustat - TRILO2GY
Three-times-weekly dosing regimen for vadadustat
Phase 3 YE 2018
Phase 3 trial to be initiated late 2017 or early 2018 with data due by the end of 2018.
AKBA
$14.94
+0.1  (+0.67%)
Vadadustat - FO2RWARD
Renal anemia
Phase 2
Phase 2 data due by the end of 2018.
AKCA
$19.52
+0.36  (+1.9%)
AKCEA-APO(a)-LRx
Hyperlipoproteinemia(a) and established cardiovascular disease
Phase 2b 2018
Phase 2b initiation announced March 30, 2017. Data due 2018.
ALDX
$6.45
-0.05  (-0.77%)
ADX-102
Allergic conjunctivitis
Phase 2b 2H 2018
Phase 2b data released June 14 2017 - primary endpoint not met. However, Phase 3 trial is planned for 1H 2018 with data due 2H 2018.
ALDX
$6.45
-0.05  (-0.77%)
ADX-102
Noninfectious anterior uveitis
Phase 3 2H 2018
Phase 3 trial initiation announced April 27, 2017 with data due 2H 2018.
ALDX
$6.45
-0.05  (-0.77%)
ADX-102
Sjögren-Larsson Syndrome (SLS)
Phase 2 2H 2018
Phase 3 trial to be initiated 1H 2018 with initial data due 2H 2018.
ALNY
$125.79
+2.13  (+1.72%)
ALN-CC5 (cemdisiran)
Atypical hemolytic-uremic syndrome (aHUS)
Phase 1/2 2018
Phase 2 trial initiation announced September 26, 2017 with initial data due 2018.
ALXN
$114.23
+1.13  (+1%)
ALXN1210
Paroxysmal nocturnal hemoglobinuria (PNH)
Phase 1/2 2Q 2018
Phase 3 data due 2Q 2018.
ARGS
$0.15
+0  (+2.09%)
ARGX-113
Pemphigus vulgaris (PV)
Phase 2 2H 2018
Phase 2 initiation announced September 26, 2017 with interim data due 2H 2018.
ARGX
$57.93
-1.54  (-2.59%)
ARGX-113
Immune thrombocytopenia (ITP)
Phase 2 2H 2018
Phase 2 data due 2H 2018.
ATNX
$16.80
-0.03  (-0.18%)
Oraxol
Metastatic breast cancer
Phase 3 2018
Phase 3 second interim analysis due 2018.
AUPH
$4.66
-0.1  (-2.13%)
Voclosporin
Dry eye syndrome
Phase 2 2H 2018
Phase 2 trial to be initiated 2Q 2018 with data due 2H 2018.
AUPH
$4.66
-0.1  (-2.13%)
Voclosporin
Focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD)
Phase 2 2H 2018
Phase 2 trial to be initiated 1H 2018. Interim data readouts are anticipated 2H 2018.
AZN
$33.10
-0.2  (-0.59%)
Farxiga - DECLARE
Type-2 diabetes
Phase 3 2H 2018
Cardiovascular outcome data due 2H 2018.
AZN
$33.10
-0.2  (-0.59%)
Benralizumab - TERRANOVA
COPD
Phase 3 2H 2018
Phase 3 data due 2H 2018.
AZN
$33.10
-0.2  (-0.59%)
Farxiga - DECLARE
Cardiovascular Outcomes
Phase 3
Phase 3 data due 2H 2018.
AZN
$33.10
-0.2  (-0.59%)
Durvalumab +/- tremelimumab (NEPTUNE)
Lung cancer
Phase 3 2H 2018
Phase 3 data due 2H 2018.
AZN
$33.10
-0.2  (-0.59%)
Anifrolumab
Lupus
Phase 3 2H 2018
Phase 3 data due 2H 2018.
BIIB
$326.39
+2.84  (+0.87%)
Raxatrigine - BIIB074 (Nav1.7 inhibitor)
Painful Lumbosacral Radiculopathy (PLSR)
Phase 2 2018
Phase 2 initiated 2016. Data due in 2018.
BLPH
$2.50
+0.08  (+3.3%)
INOpulse delivery device
Pulmonary Hypertension associated with Idiopathic Pulmonary Fibrosis (PH-IPF)
Phase 2 YE 2018
Phase 2 initiated May 2016. Data presented at American Thoracic Society (ATS) Conference, May 21 2017. Phase 2b planned for early 2018 with data due late 2018.
BLPH
$2.50
+0.08  (+3.3%)
INOpulse delivery device
Pulmonary Arterial Hypertension (PAH)
Phase 3
Phase 3 commenced enrollment June 2016. Interim analysis and top-line data due 2018.
BLRX
$1.07
+0.02  (+1.98%)
BL-8040
Consolidation treatment for AML cancer patients
Phase 2b
Phase 2b initiated August 2015. Interim analysis due in 2018, with top-line results expected in 2019.
BMY
$62.76
+0.63  (+1.01%)
CM-602 – Opdivo + Elo + SOC
Myeloma
Phase 3
Phase 3 data due 2H 2018. Noted September 6, 2017 that trial has been placed on partial hold.
BMY
$62.76
+0.63  (+1.01%)
CM-459 – Opdivo
First-line Hepatocellular carcinoma (HCC) - cancer
Phase 3
Phase 3 data due 2H 2018.
BYSI
$30.22
+1.11  (+3.81%)
Plinabulin
Non small cell lung cancer - refractory
Phase 3 2018
Phase 3 trial initiated 2016. Interim data due 2018. Final data due 1Q 2019.
CELG
$109.32
+1.08  (+0.99%)
REVLIMID - ROBUST
First-line ABC Diffuse large B-cell lymphoma (DLBCL)
Phase 3 2018
Phase 3 data due 2018.
CELG
$109.32
+1.08  (+0.99%)
MM-007 OPTIMISMM
Multiple Myeloma - refractory
Phase 3 2018
Phase 3 data due 2018.
CELG
$109.32
+1.08  (+0.99%)
Oral Azacitidine - CC-486-AML-001
Post induction AML Maintenance
Phase 3 2018
Phase 3 data due 2018.
CELG
$109.32
+1.08  (+0.99%)
ABRAXANE - PANC-003 apact
Adjuvant Therapy in Surgically Resected Pancreatic Cancer
Phase 3 YE 2018
Phase 3 data due year end 2018.
CELG
$109.32
+1.08  (+0.99%)
ABRAXANE - IMpower 130 ( I/O Combo)
Non-small cell lung cancer (NSCLC)
Phase 3 2018
Phase 3 data due 2018.
CELG
$109.32
+1.08  (+0.99%)
ABRAXANE - IMpower 131 ( I/O Combo)
Non-small cell lung cancer (NSCLC)
Phase 3 2018
Phase 3 data due 2018.
CELG
$109.32
+1.08  (+0.99%)
ABRAXANE - IMPassion ( I/O Combo)
Triple Negative Metastatic Breast Cancer
Phase 3
Phase 3 data due 2018.
CFRX
$0.96
+0.05  (+5.43%)
CF-301
Serious infections caused byStaph aureus including MRSA
Phase 2 4Q 2018
Phase 2 initiation announced May 25, 2017 - data due 4Q 2018.
CNAT
$4.14
+0.05  (+1.22%)
Emricasan
NASH cirrhosis - ENCORE-PH trial
Phase 2 2H 2018
Phase 2b initiated November 2016. Data due 2H 2018.
CNCE
$27.27
+1.01  (+3.84%)
CTP-543
Alopecia areata
Phase 2a 2H 2018
Phase 2 clinical hold placed May 17, 2017 lifted July 10, 2017. Trial completion due 2H 2018.
EGRX
$57.36
+1.68  (+3.02%)
Fulvestrant
Breast cancer
Phase 3 4Q 2018
Pivotal trial initiation announced December 7, 2017. Trial completion and NDA filing due 4Q 2018.
EIGR
$12.00
-0.1  (-0.83%)
Exendin 9-39
Post-Bariatric Hypoglycemia (PBH)
Phase 2 4Q 2018
Phase 2 to be initiated 4Q 2017 with completion 4Q 2018.
EIGR
$12.00
-0.1  (-0.83%)
Ubenimex - ULTRA
Secondary lymphedema
Phase 2 4Q 2018
Phase 2 dosing commenced July 2016. Enrollment to be completed 4Q 2017. Trial completion 4Q 2018.
EPZM
$12.60
+0  (+0%)
Tazemetostat
Adult patients with mesothelioma characterized by BAP1 loss-of-function
Phase 2 2018
Phase 2 dosing commenced August 2016. Enrollment completed June 2017 with data due 2018.
ESPR
$58.08
+0.32  (+0.55%)
Bempedoic Acid/ Ezetimibe (1002FDC-053)
Hypercholesterolemia
Phase 3 4Q 2018
Phase 3 initiation announced November 6, 2017. Data due 4Q 2018.
FGEN
$41.25
-0.7  (-1.67%)
Roxadustat - ANDES
Anaemia
Phase 3 2018
Phase 3 data due 2018.
GEMP
$8.02
+0.01  (+0.12%)
Gemcabene - AZURE-1
Nonalcoholic steatohepatitis (NASH) / Nonalcoholic fatty liver disease (NAFLD)
Phase 2 2H 2018
Phase 2 trial to be initiated in 4Q 2017 with data due 2H 2018.
GILD
$75.29
+0.94  (+1.27%)
GS-9876
Phase 2 2H 2018
Phase 2 trial to be completed 2H 2018.
GILD
$75.29
+0.94  (+1.27%)
GS-5734
Ebola
Phase 2 2H 2018
Phase 2 trial to be completed 2H 2018.
GILD
$75.29
+0.94  (+1.27%)
Axicabtagene ciloleucel - KTE-C19 (ZUMA-2)
Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL) - cancer
Phase 2
Phase 2 pivotal initiated November 2015. Data due 2018.
GILD
$75.29
+0.94  (+1.27%)
Axicabtagene ciloleucel - KTE-C19 (ZUMA-3)
Adult patients with r/r ALL - cancer
Phase 1/2
Phase 2 data due 2018. Phase 1 data released at ASCO June 5, 2017. Complete remission 73%. Data released at ASH 2017 showed complete remission of 71%.
GILD
$75.29
+0.94  (+1.27%)
Axicabtagene ciloleucel - KTE-C19 (ZUMA-4)
Pediatric and young adult patients with r/r ALL - cancer
Phase 1/2
Phase 2 data due 2018.
GSK
$35.08
-0.17  (-0.47%)
Closed Triple - CAPTAIN
Asthma
Phase 3
Phase 3 data due 2H 2018.
GTXI
$13.00
+0.15  (+1.16%)
Enobosarm
Postmenopausal women with stress urinary incontinence (SUI)
Phase 2 YE 2018
Phase 2 data due by the end of 2018.
GWPH
$129.85
-0.97  (-0.75%)
Epidiolex
Dravet Syndrome
Phase 3 2H 2018
Second Phase 3 trial initiated mid April 2015. Data due 2H 2018.
GWPH
$129.85
-0.97  (-0.75%)
Epidiolex
Tuberous Sclerosis Complex
Phase 3 2H 2018
Phase 3 data due 2H 2018.
HALO
$19.83
-0.71  (-3.46%)
PEGPH20 - HALO-301
Pancreatic cancer
Phase 3 Late 2018
Phase 3 dosing initiated March 2016. PFS data potentially due late 2018.
HTBX
$0.37
-0  (-1.07%)
HS-110 and nivolumab (Opdivo)
Non-small cell lung cancer (NSCLC)
Phase 1b 2H 2018
Phase 2 data due 2H 2018.
IMGN
$6.58
-0.12  (-1.8%)
Kadcyla (KATHERINE).
HER2-positive breast cancer - residual invasive disease
Phase 3
Phase 3 data due in 2018.
IMRN
$5.12
+0  (+0%)
IMM-529
C. difficile infection
Phase 1/2
Phase 1/2 trial enrollment to commence mid-September 2017 with data due 4Q 2018.
INVA
$13.40
+0.12  (+0.9%)
Closed Triple
Asthma
Phase 3
Phase 3 data due 2H 2018.
IOVA
$8.35
+0.2  (+2.45%)
LN-145
Cervical cancer
Phase 2
Phase 2 dosing has commenced - noted August 16, 2017. Initial data due 2018.
JNJ
$142.55
+0.9  (+0.63%)
STELARA (USTEKINUMAB)
Ulcerative colitis
Phase 3
Phase 3 trial to be completed in 2018.
KPTI
$9.20
-0.05  (-0.55%)
Selinexor - SADAL
Cancer - Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 2b 2H 2018
Phase 2b additional interim data released June 23, 2017 at EHA. Final top-line data due 2H 2018.
LLY
$87.42
+0.92  (+1.06%)
Flortaucipir F 18 (Tau imaging agent)
Alzheimer's disease
Phase 3 2018
Phase 3 ongoing. Data due 2018 (internal readout).
MACK
$10.39
+0.21  (+2.06%)
MM-121
Cancer - Heregulin Positive Non-Small Cell Lung Cancer
Phase 2
Phase 2 initiated mid Feb 2015. Data due 2H 2018.
MBRX
$1.70
+0.01  (+0.59%)
Annamycin
Acute myeloid leukemia (AML) - cancer
Phase 1/2
Phase 1/2 data due 2018.
MRK
$56.33
+0.32  (+0.57%)
Epacadostat with Keytruda - ECHO-301
Cancer - first-line metastatic melanoma.
Phase 3
Phase 3 initiated June 2016. Initial data due 2018.
MRNS
$8.91
-0.42  (-4.51%)
Ganaxolone
Refractory status epilepticus (RSE)
Phase 2 2018
Phase 2 data due 2018.
NBIX
$70.50
+0.08  (+0.11%)
INGREZZA - T-Force GOLD
Tourette syndrome - juvenile
Phase 2b Late-2018
Phase 2 data released May 23 - primary endpoint not met. Phase 2b trial initiation announced October 25, 2017. Top-line data due late 2018.
NVCR
$20.00
+0.05  (+0.25%)
Tumor Treating Fields (TTFields) STELLAR
Mesothelioma
Phase 2 2018
Phase 2 enrollment completion announced March 31, 2017. Data due 2018.
NVS
$84.58
+0.11  (+0.13%)
QVM149
Asthma
Phase 3 2018
Phase 3 data due 2018.
OBSV
$9.80
+0.03  (+0.3%)
OBE022 - PROLONG
Pre-term labor
Phase 2a YE 2018
Phase 2a trial initiation announced December 5, 2017. Part B preliminary data due late 2018.
OCUL
$4.83
+0.08  (+1.68%)
OTX-TP
Glaucoma and ocular hypertension
Phase 3 2H 2018
Phase 3 initiated October 2016. Data due 2H 2018.
ONCS
$1.67
-0.04  (-2.6%)
ImmunoPulse IL-12 - PISCES
Melanoma - cancer
Phase 2b 2018
Phase 2 initiation of dosing announced December 14, 2017 with initial data due 2018.
PFE
$37.07
+0.6  (+1.65%)
Tanezumab
Cancer pain
Phase 3
Phase 3 ongoing. Estimate data due 2018 using clinicaltrials.gov data.
PLX
$0.62
-0  (-0.3%)
PRX-102
Fabry disease
Phase 3
Phase 3 dosing commenced October 2016. Enrollment to be completed 2H 2017 with data in 2018.
PRQR
$2.85
+0.05  (+1.78%)
QR-010
Genetic blindness
Phase 1/2 2018
Phase 1/2 commencement of dosing announced November 14, 2017. Interim safety and efficacy 6-month data due 2018, full 12 month data due 2019.
PULM
$1.48
+0.01  (+0.68%)
PUR1800
Acute exacerbation of chronic obstructive pulmonary disease (AECOPD)
Phase 2
Phase 2 trial to be initiated mid-2018 with data due late 2018.
RDHL
$4.85
+0.05  (+1.04%)
RHB-105 - ERADICATE Hp 2
H. pylori
Phase 3 2H 2018
Phase 3 final data released March 2016. Additional Phase 3 trial initiation announced June 15, 2017 with data due 2H 2018.
RETA
$25.21
+0.38  (+1.53%)
Bardoxolone methyl - CATALYST
Pulmonary arterial hypertension associated with connective tissue disease - CTD-PAH
Phase 3 2H 2018
Phase 3 commenced enrollment October 2016 with data due 2H 2018.
RIGL
$3.50
-0.08  (-2.11%)
Fostamatinib
IgA nephropathy
Phase 2
Phase 2 preliminary data released January 5, 2017. Enrollment of second cohort to be completed in 2017 with data due in 2018.
SBBP
$6.25
+0.1  (+1.62%)
COR-003 (levoketoconazole) - LOGICS
Endogenous Cushing’s syndrome
Phase 3 4Q 2018
Phase 3 top-line data expected in 4Q 2018.
SGEN
$52.08
+0.26  (+0.49%)
ADCETRIS in combination with chemotherapy - ECHELON-2
Frontline CD30-positive mature T-cell lymphomas - cancer
Phase 3
Phase 3 enrollment completed November 2016. Data are due in 2018.
SNNA
$25.00
-0.31  (-1.23%)
SNA-001
Reduction of light-pigmented hair
Phase 3 2H 2018
Pivotal data due 2H 2018.
SNNA
$25.00
-0.31  (-1.23%)
SNA-001
Acne
Phase 3 2H 2018
Pivotal data due 2H 2018.
SVRA
$15.15
+0.14  (+0.89%)
Molgradex - IMPALA
Autoimmune pulmonary alveolar proteinosis (PAP)
Phase 3
Phase 3 data due by the end of 2018.
TBPH
$27.66
+0.34  (+1.24%)
Closed Triple - CAPTAIN
Asthma
Phase 3
Phase 3 data due 2H 2018.
TCON
$3.00
+0.05  (+1.69%)
TRC105
Gestational Trophoblastic Neoplasia cancer
Phase 2 2018
Phase 2 planned for 2016. Data due 2018.
TCON
$3.00
+0.05  (+1.69%)
TRC102
Mesothelioma cancer
Phase 2 2018
Phase 2 initiated October 2015. Data are due in 2018.
TCON
$3.00
+0.05  (+1.69%)
TRC105 (TAPPAS)
Angiosarcoma cancer
Phase 3 2H 2018
Phase 3 dosage of first patient announced February 16, 2017. Interim analysis 2H 2018.
UTHR
$136.90
+1.12  (+0.82%)
Esuberaprost - BEAT
Pulmonary arterial hypertension (PAH)
Phase 3
Phase 3 enrollment has completed. Data possible 2018.
UTHR
$136.90
+1.12  (+0.82%)
Orenitram
Pulmonary arterial hypertension (PAH)
Phase 3
Phase 3 data due 2H 2018. Independent data monitoring committee (DMC) noted September 8, 2017 that the trial should continue following its interim analysis.
VNDA
$14.15
+0.1  (+0.71%)
HETLIOZ (tasimelteon)
Smith-Magenis Syndrome
Phase 3 2018
Phase 3 initiated 4Q 2016. Data due 2018.
VRNA
$12.25
+0.33  (+2.75%)
RPL554
COPD
Phase 2b
Phase 2a data released September 7, 2017. Phase 2b trial enrolling with data due 2H 2018.
VTGN
$1.09
-0.01  (-0.91%)
AV-101
Adjunctive Treatment Major Depressive Disorder
Phase 2 2H 2018
Phase 2 trial to commence 1Q 2018 with completion due 2H 2018.
XBIT
$4.34
-0.13  (-2.91%)
XBIO-101
Endometrial cancer
Phase 2 YE 2018
Phase 2 data due before the end of 2018.
XNCR
$21.36
+0.35  (+1.66%)
XmAb5871
Systemic Lupus Erythematosus (SLE)
Phase 2 YE 2018
Phase 2 trial initiated March 2016. Initial data due late 2018.
CLSD
$6.07
+0.13  (+2.18%)
Suprachoroidal CLS-TA - SAPPHIRE
Macular edema associated with retinal vein occlusion (RVO)
Phase 3 1Q 2019
Announced enrollment of the first patient in its Phase 3 trial - February 16, 2017. Preliminary data due 1Q 2019.
CLSN
$2.78
-0.02  (-0.57%)
ThermoDox - OPTIMA
Hepatocellular carcinoma - liver cancer
Phase 3 1Q 2019
Original Phase 3 trial failed to meet primary endpoint. New Phase 3 trial initiated with enrollment to be completed by mid-2018 with first interim analysis due 1Q 2019.
GSK
$35.08
-0.17  (-0.47%)
Danirixin
Chronic obstructive pulmonary disease (COPD)
Phase 2b
Phase 2b data likely due 1Q 2019.
PRTO
$1.88
+0.03  (+1.55%)
Vonapanitase (PRT-201) PATENCY-2
Chronic kidney disease (CKD) patients undergoing surgical placement of an arteriovenous fistula (AVF)
Phase 3
Phase 3 enrollment to be completed 1Q 2018. Data due 1Q 2019.
ABBV
$97.47
+1.17  (+1.21%)
ABBV-8E12
Progressive supranuclear palsy (PSP)
Phase 2
Phase 2 initiation announced January 25, 2017. Estimated Primary Completion Date: May 2019
ATNM
$0.64
+0  (+0.15%)
Iomab-B
Hematopoietic Stem Cells Transplantation
Phase 3
Phase 3 initiated June 2016. Enrollment to be completed by the end of 2018. Data due 2H 2019
BMY
$62.76
+0.63  (+1.01%)
CM-568 - Opdivo + Yervoy
First-line Non-small cell lung cancer (NSCLC)
Phase 2
Phase 2 data due 2H 2018 – 1H 2019.
CNAT
$4.14
+0.05  (+1.22%)
Emricasan
NASH fibrosis - ENCORE-NF trial
Phase 2 1H 2019
Phase 2 completion of enrollment noted August 14, 2017. Data are due 1H 2019.
FBIO
$3.50
-0.02  (-0.57%)
CEVA101
Severe Traumatic Brain Injury
Phase 2
Phase 2 data in adults due 1H 2019.
GBT
$37.84
-1.56  (-3.97%)
GBT440 - HOPE
Sickle cell disease in adults
Phase 3 1H 2019
Announced January 18, 2017 that Phase 3 enrollment has commenced. DSMB safety review noted November 13, 2017 that trial may proceed as planned. Top-line data due 1H 2019.
GSK
$35.08
-0.17  (-0.47%)
Tapinarof
Atopic dermatitis, psoriasis
Phase 3
Phase 3 data due 1H 2019.
GSK
$35.08
-0.17  (-0.47%)
Inhaled PI3Kδ inhibitor
Chronic obstructive pulmonary disease (COPD)
Phase 2b
Phase 2b data due 1H 2019.
ICPT
$61.83
+0.22  (+0.35%)
Ocaliva (Obeticholic acid (OCA)) - REGENERATE
Adult nonalcoholic steatohepatitis (NASH) patients.
Phase 3 1H 2019
Phase 3 data due 1H 2019.
RYTM
$27.28
-0.76  (-2.72%)
Setmelanotide
POMC deficiency obesity
Phase 3 1H 2019
Phase 3 data due 1H 2019.
SNDX
$8.61
-0.39  (-4.34%)
Entinostat plus Tecentriq - ENCORE 603
Phase 1/2 1H 2019
Phase 2 portion of trial to complete enrollment 1H 2018 with data due 1H 2019.
SNNA
$25.00
-0.31  (-1.23%)
SNA-120
Pruritus associated with psoriasis
Phase 2b 1H 2019
Second Phase 2b trial initiation announced October 24, 2017 - top-line data due 1H 2019.
TBPH
$27.66
+0.34  (+1.24%)
Telavancin
Bacteremia
Phase 3 2018/19
Phase 3 data due 2018 or 2019.
AKBA
$14.94
+0.1  (+0.67%)
Vadadustat - INNO2VATE
Anemia related to chronic kidney disease who are undergoing dialysis (DD-CKD)
Phase 3
Phase 3 initiated August 2016. NDA filing pending positive data due 2019. Estimate data release mid-2019.
AKBA
$14.94
+0.1  (+0.67%)
Vadadustat - PRO2TECT
Non-dialysis patients with anemia related to CKD (NDD-CKD)
Phase 3
Phase 3 initiated January 2016. NDA filing pending positive data due 2019. Estimate data release mid-2019.
ALNY
$125.79
+2.13  (+1.72%)
Fitusiran (ATLAS)
Hemophilia
Phase 3 Mid-late 2019
Phase 3 program initiation announced July 7, 2017 with initial data due mid-late 2019. Dosing has yet to be initiated - noted September 7, 2017 that Fitusiran program suspended dosing due to fatal thrombotic event. Reinitiation targeted around YE 2017.
ABBV
$97.47
+1.17  (+1.21%)
Venetoclax
Relapsed or refractory multiple myeloma
Phase 3
Phase 3 trial initiated July 2016. Data due 2019.
AFMD
$1.23
-0.08  (-5.77%)
AFM13
Hodgkin Lymphoma - Cancer
Phase 2
Phase 2a full data due 2019.
AGN
$173.10
+2.15  (+1.26%)
RAPASTINEL
Major depressive disorder (MDD)
Phase 3
Phase 3 initiated October 2016. Data due 2019.
AKCA
$19.52
+0.36  (+1.9%)
AKCEA-ANGPTL3-LRx
Non-alcoholic fatty liver disease (NAFLD), Hypertriglyceridemia and Type 2 Diabetes Mellitus
Phase 2 2019
Phase 2 initiation announced December 14, 2017. Top-line data due 2019.
ANAB
$89.89
+1.13  (+1.27%)
ANB020
Moderate-to-severe adult atopic dermatitis
Phase 2b 2019
Phase 2a positive data released October 10, 2017. Phase 2b trial to be initiated 1H 2018 with data due 2019.
AZN
$33.10
-0.2  (-0.59%)
AZD3293
Early Alzheimer's disease
Phase 3 2019
Phase 3 data due 2019.
AZN
$33.10
-0.2  (-0.59%)
Durvalumab +/- tremelimumab (DANUBE)
Bladder cancer
Phase 3 2019
Phase 3 data due 2019.
AZN
$33.10
-0.2  (-0.59%)
Brilinta (THEMIS)
Type 2 Diabetes
Phase 3 2019
Phase 3 data due 2019.
BCLI
$3.83
-0.02  (-0.48%)
NurOwn
Amytrophic lateral sclerosis (ALS)
Phase 3 2019
Phase 3 patient enrollment announced October 16, 2017. Top-line data due 2019.
BMRN
$89.43
+0.9  (+1.01%)
Vosoritide
Achondroplasia
Phase 3 2H 2019
Phase 3 trial initiation announced December 12, 2016. Top-line data due 2H 2019.
CELG
$109.32
+1.08  (+0.99%)
REVLIMID - MAGNIFY NHL-010
Untreated Activated B-Cell Diffuse large B-cell lymphoma (DLBCL)
Phase 3
Phase 3 data due 2019.
CHMA
$1.89
+0.04  (+2.16%)
Mycapssa - OPTIMAL
Acromegaly
Phase 3 2019
Phase 3 trial to commence enrollment 2H 2017 with data due 2019.
CNAT
$4.14
+0.05  (+1.22%)
Emricasan
NASH cirrhosis - ENCORE-LF trial
Phase 2b 2019
Phase 2b data due 2019.
GALE
$0.30
-0.02  (-6.35%)
NeuVax in combination with Herceptin
Breast cancer - HER2 3+
Phase 2 4Q 2019
Phase 2 data due 4Q 2019.
GSK
$35.08
-0.17  (-0.47%)
Mepolizumab - SYNAPSE
Nasal polyps
Phase 3
Phase 3 trial initiation announced June 27, 2017. To be completed in 2019.
IMGN
$6.58
-0.12  (-1.8%)
Kadcyla (KAITLIN)
HER2-positive breast cancer - adjuvant use
Phase 3
Phase 3 data due in 2019.
INCY
$95.29
-0.68  (-0.71%)
Ruxolitinib - REACH 3
Steroid-refractory chronic GVHD (Graft versus host disease)
Phase 3 2019
Phase 3 trial commenced June 2017.Expected completion 2019.
JNJ
$142.55
+0.9  (+0.63%)
INVOKANA - CREDENCE
Diabetic Kidney Disease
Phase 3
Phase 3 data due 2019.
JNJ
$142.55
+0.9  (+0.63%)
DARZALEX (Daratumumab)
Frontline multiple myeloma (transplant)
Phase 3
Phase 3 data likely due 2019.
KPTI
$9.20
-0.05  (-0.55%)
Selinexor - SEAL
Dedifferentiated liposarcoma
Phase 2/3 2019
Phase 2/3 trial initiated January 2016. Topline data for the Phase 2 portion released September 20, 2017 - PFS HR 0.60. Phase 3 data due by end of 2019.
KPTI
$9.20
-0.05  (-0.55%)
Selinexor - BOSTON
Multiple myeloma
Phase 3 2019
Phase 3 trial initiation announced June 7, 2017. Enrollment to be completed 2018 with data due 2019.
MDCO
$27.20
-0.05  (-0.19%)
Inclisiran
Hypercholesterolemia
Phase 3
Phase 3 trial commencement announced November 10, 2017. Data due by end of 2019.
MRK
$56.33
+0.32  (+0.57%)
MK-8931 (019) - Verubecestat
Mild-to-moderate Alzheimer's
Phase 3
Fully enrolled. Data due in 2019.
NVS
$84.58
+0.11  (+0.13%)
QAW039 (fevipiprant)
Asthma
Phase 3 2019
Phase 3 data due 2019.
NVS
$84.58
+0.11  (+0.13%)
OMB157 (ofatumumab)
Relapsing multiple sclerosis
Phase 3 2019
Phase 3 data due 2019.
NVS
$84.58
+0.11  (+0.13%)
Entresto - PARAGON
HF-pEF (heart failure with preserved ejection fraction)
Phase 3 2019
Phase 3 expected completion due 2019.
NVS
$84.58
+0.11  (+0.13%)
Entresto - PARADISE
AMI (acute myocardial infarction)
Phase 3 2019
Phase 3 trial completion due 2019. Filing 2020.
NVS
$84.58
+0.11  (+0.13%)
AIN457 (Cosentyx)
Non-radiographic axial SpA
Phase 3 2019
Phase 3 data due 2019.
OBSV
$9.80
+0.03  (+0.3%)
OBE2109 - PRIMROSE
Uterine fibroids
Phase 3 2H 2019
Phase 3 trial initiation announced April 25, 2017 with data due 2H 2019.
RETA
$25.21
+0.38  (+1.53%)
Bardoxolone methyl - CARDINAL
Chronic Kidney Disease Caused by Alport Syndrome
Phase 3 2H 2019
Data from Phase 2 part of trial released July 24, 2017. Phase 3 data due 2H 2019.
RETA
$25.21
+0.38  (+1.53%)
Omaveloxolone - MOXIe
Friedreich’s ataxia (FA)
Phase 2 2H 2019
Phase 2 initial data released June 1, 2017. Primary endpoint not met. Part 2 commencement annnounced October 23, 2017 with data due 2H 2019.
ABBV
$97.47
+1.17  (+1.21%)
ABBV-8E12
Alzheimer's disease
Phase 2
Phase 2 initiation announced January 25, 2017. Estimated Primary Completion Date: April 2020.
ADXS
$3.07
+0.02  (+0.65%)
Axalimogene filolisbac - AIM2CERV Trial
High-risk, locally advanced cervical cancer
Phase 3 2020/21
Announced Phase 3 first patient dosed - February 6, 2017. Enrollment continues as of August 2017. Data due 2020 or 2021.
AGN
$173.10
+2.15  (+1.26%)
RELAMORELIN
Diabetic Gastroparesis
Phase 3
Phase 3 to be initiated 2H 2017 with top-line data due 2020.
AZN
$33.10
-0.2  (-0.59%)
Durvalumab (ADJUVANT)
Adjuvant Non-small cell lung cancer (NSCLC)
Phase 3 2020
Phase 3 data due 2020.
CATB
$1.65
-0.08  (-4.07%)
Edasalonexent (CAT-1004)
Duchenne muscular dystrophy (DMD)
Phase 3 2020
Phase 1/2 top-line data released January 31 - primary endpoint not met. Data from open-label presented October 4, 2017 deemed sufficient to proceed to Phase 3 development - to commence 1H 2018 with data due 2020.
CELG
$109.32
+1.08  (+0.99%)
REVLIMID - MAGNIFY NHL-008
Relapsed or Refractory Indolent Lymphoma
Phase 3 2020
Phase 3 data due 2020.
CHMA
$1.89
+0.04  (+2.16%)
Mycapssa - MPOWERED
Maintenance treatment of adult acromegaly
Phase 3 2020
Phase 3 data due 2020.
GSK
$35.08
-0.17  (-0.47%)
Daprodustat - ASCEND-D
Anemia
Phase 3